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HALTED INNOVATION: THE EXPANSION OF FEDERAL JURISDICTION 
OVER MEDICINE AND THE HUMAN BODY 
 
Myrisha S. Lewis* 
 
Abstract 
Modern medical innovations are blurring the line between medical 
practice and medical devices and drugs. Historically, many techniques 
have been developed in medicine, without any interference from the 
federal government, as medical practice is (and has historically been) an 
area of state jurisdiction. Over the past two decades, however, the U.S. 
Food and Drug Administration (FDA) has been exerting jurisdiction over 
the human body and the practice of medicine by targeting new medical 
techniques for oversight and subjecting the continued use of those 
treatments to onerous and legally questionable regulatory requirements 
that hinder the use of those treatments in practice.  
This Article examines developing innovations in medicine and the life 
sciences, including gene editing (and CRISPR-Cas9, a system of gene 
editing that has been the subject of significant media coverage due to its 
wide-ranging potential uses), forms of assisted reproductive technology 
that could prevent the transmission of genetic diseases, stem cell 
therapies, and fecal microbiota transplants. The Article makes several 
claims. First, the Article argues that innovations in the life sciences largely 
fall outside of the jurisdiction of the FDA. Second, the FDA is applying a 
regime intended to regulate medical devices and pharmaceuticals to new 
innovations in the life sciences, which has a chilling effect on innovation 
and patient health. The Article also reveals that States—due to their 
historic police powers over the practice of medicine—retain a critical 
piece of jurisdiction over the life sciences such that the only method of 
accurately and adequately regulating the life sciences must include the 
States. Ultimately, it is critical that the regulatory apparatus surrounding  
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the life sciences be improved, as the pace of innovation indicates that the 
regulation of the life sciences will continue to be salient in the near and 




Scientific discovery and innovation have proven to be the keys to improving 
patient outcomes. Over the past century, scientific discoveries have resulted in the 
widespread use of organ transplantation, pacemakers, increasingly effective 
pharmaceuticals (which treat diseases such as Human Immunodeficiency Virus 
(HIV) and cancer more effectively, and in some cases, can cure diseases such as 
Hepatitis C), stem cell treatments, new vaccines (such as the Human Papillomavirus 
(HPV) vaccine), and more recently, gene therapy.1  
Innovation is encouraged through various methods, including the societal 
celebration of “genius” and the use of legislation to create incentives for those who 
might innovate and improve the public good.2 The recently enacted 21st Century 
Cures Act, a piece of federal legislation that has been described as “landmark,”3 the 
                                               
1 See, e.g., THOMAS E. STARZL, THE PUZZLE PEOPLE: MEMOIRS OF A TRANSPLANT 
SURGEON (2003); Our Approach for Pacemakers, STANFORD HEALTH CARE, 
https://stanfordhealthcare.org/medical-treatments/p/pacemaker.htm [https://perma.cc/VX 
6X-K9XS] (last visited June 10, 2018); Michelle Andrews, FDA’s Approval of a Cheaper 
Drug for Hepatitis C Will Likely Expand Treatment, NPR (Oct. 4, 2017, 5:00 AM), 
https://www.npr.org/sections/health-shots/2017/10/04/555156577/fdas-approval-of-a-
cheaper-drug-for-hepatitis-c-will-likely-expand-treatment [https://perma.cc/URJ5-WNJH]; 
see also Medical Milestones: Celebrating Key Advances Since 1840, BRITISH MED. J. Suppl: 
S1 (M. Chew and K Sharrock eds., 2007), http://www.bmj.com/content/suppl/2007/01/18/ 
334.suppl_1.DC2/milestones.pdf [https://perma.cc/EJ84-XJPR]; Gene Therapy for 
Children, Teens and Young Adults, DANA-FARBER CANCER AND BLOOD DISORDERS CTR., 
http://www.danafarberbostonchildrens.org/innovative-approaches/gene-therapy.aspx 
[https://perma.cc/5EJM-N55L] (last visited June 10, 2018); Dan Childs & Susan Kansagra, 
10 Health Advances that Changed the World, ABC NEWS (Sept. 20, 2007), 
http://abcnews.go.com/Health/TenWays/story?id=3605442&page=1 [https://perma.cc/E6 
N8-6Z9R]; 10 Medical Advances in the Last 10 Years, CNN (June 5, 2013), 
http://www.cnn.com/2013/06/05/health/lifeswork-medical-advances/index.html 
[https://perma.cc/KJ86-CKX3]. 
2 See, e.g., Gaia Bernstein, In the Shadow of Innovation, 31 CARDOZO. L. REV. 2257, 
2257–60, 2290 (2010); Mark A. Lemley & R. Anthony Reese, Reducing Digital Copyright 
Infringement Without Restricting Innovation, 56 STAN. L. REV. 1345, 1349–50 (2004) 
(referring to the “social value” of innovation and how certain legal and regulatory actions 
may stifle innovation); Arti K. Rai, The Information Revolution Reaches Pharmaceuticals: 
Balancing Innovation Incentives, Cost, and Access in the Post-Genomics Era, 2001 U. ILL. 
L. REV. 173 (2001); Richard A. Merrill, The Architecture of Government Regulation of 
Medical Products, 82 VA. L. REV. 1753, 1800 (1996) (“The Medical Device Amendments 
represented a conscious legislative attempt to avoid what some viewed as the innovation-
stifling effects of FDA’s drug approval system.” (citation omitted)). 
3 Remarks by Acting FDA Commissioner Stephen M. Ostroff, M.D. FDLI Annual 
Conference: May 4, 2017, Washington, DC, 72 FOOD & DRUG L.J. 378, 381 (2017) (“Let me 
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“most significant overhaul of the U.S. Food and Drug Administration . . . in 
decades,”4 and a “bipartisan victory,”5 uses the word “innovation” sixty-five times.6 
The 21st Century Cures Act, which was enacted in December 2016, committed $6.3 
billion, to be distributed over seven years, to fund a number of projects, including 
the Beau Biden Cancer Moonshot, the Precision Medicine Initiative, the BRAIN 
Initiative, and projects that aim to address the opioid crisis, mental illness, 
Alzheimer’s disease, and other diseases, in addition to creating an accelerated FDA 
review process for a new category of drugs that are classified as “regenerative 
advanced therapies.”7 
In signing the 21st Century Cures Act into law in December 2016, President 
Obama stated: 
 
Over the last eight years, one of my highest priorities as President has 
been to unleash the full force of American innovation to some of the 
biggest challenges that we face. That meant restoring science to its rightful 
place. It meant funding the research and development that’s always kept 
America on the cutting edge . . . . It meant investing in the medical 
                                               
now switch over to medical products. Without question, the biggest change from last year is 
the 21st Century Cures Act. This is landmark legislation. And like any big change, it took a 
long time to develop and a lot of hard work by a lot of people inside and outside FDA. And 
it passed with overwhelming bipartisan support.”).  
4 Jacob S. Sherkow, Cancer’s IP, 96 N.C. L. REV. 297, 299 (2018). 
5 See, e.g., Norm Ornstein, A Bipartisan Victory for Medical Research in Congress, 
THE ATLANTIC (Jul. 13, 2015), https://www.theatlantic.com/politics/archive/2015/07/21st-
century-cures-act-bipartisan/398369/ [https://perma.cc/2G59-LTTB]. See also Gary E. 
Marchant & Yvonne A. Stevens, Resilience: A New Tool in the Risk Governance Toolbox 
for Emerging Technologies, 51 U.C. DAVIS L. REV. 233, 259 (2017) (“Perhaps, at least within 
the healthcare industry, the most comprehensive adaptive regulation comes in the form of 
the 21st Century Cures Act, which came into effect on December 13, 2016.” (citation 
omitted)); Zachary Liscow & Quentin Karpilow, Innovation Snowballing and Climate Law, 
95 WASH. U. L. REV. 387, 435 (2017) (“For example, according to the recently-passed 21st 
Century Cures Act, which includes prizes for innovation in healthcare, experts will pick 
particular projects.” (citation omitted)). 
6 The word “innovation” appears 60 times in the 21st Century Cures Act and the word 
“innovations” appears 5 times in the Act. See 21st Century Cures Act, Pub. L. No. 114-255, 
130 Stat. 1033 (2016), available at https://www.gpo.gov/fdsys/pkg/PLAW-
114publ255/pdf/PLAW-114publ255.pdf (providing the text of the entire statute as signed 
into law) [https://perma.cc/T3QK-SASP]. 
7 See Press Release, White House Office of the Press Secretary, Remarks by the 
President and the Vice President at the 21st Century Cures Act Bill Signing (Dec. 13, 2016), 
available at https://obamawhitehouse.archives.gov/the-press-office/2016/12/13/remarks-
president-and-vice-president-21st-century-cures-act-bill-signing [https://perma.cc/RW33-
WJ3C] [hereinafter Remarks by the President]; The 21st Century Cures Act, NAT’L INSTS. 
OF HEALTH, https://www.nih.gov/research-training/medical-research-initiatives/cures 
[https://perma.cc/4RYF-VJNH] (last visited June 10, 2018). “BRAIN” is an acronym that 
stands for “Brain Research through Advancing Innovative Neurotechnologies.” Id. 
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breakthroughs that have the power to cure disease and help all of us live 
healthier, longer lives.8 
 
Medical advances are moving away from using pharmaceuticals to treat disease 
to using parts of the human body to cure or ameliorate harmful conditions.9 New 
medical techniques focus on using a patient’s own cells or donor tissue, instead of 
pharmaceuticals or surgery, to treat ailments.10 These new treatments have a variety 
of uses at different periods in the diagnostic process, including: (1) before disease-
causing genes can be inherited (such as with mitochondrial transfer, the subject of 
much media coverage in the United Kingdom); (2) after disease-causing genes have 
been inherited but before an embryo becomes a fetus (such as with gene editing 
systems including CRISPR-Cas9, which has been the subject of a well-publicized 
patent battle); or, (3) after a disease manifests, but often fails to respond to 
conventional medical treatment (such as with autologous stem cell treatments to 
treat orthopedic conditions without invasive surgery or fecal transplants to treat C. 
difficile, an antibiotic-resistant infection commonly contracted after 
hospitalization).11 None of these aforementioned techniques fits clearly within 
existing legal structures and in spite of their differing disease targets and methods, 
all of these techniques offer great promise in improving patient health. Yet, all of 
the aforementioned techniques, in spite of their differing treatment targets, are 
subject to onerous legal requirements in the United States that are often so stringent 
that the clinical use of these techniques is effectively banned.12  
                                               
8 Remarks by the President, supra note 7. 
9 See infra note 11 and accompanying text (discussing new methods of treating ailments 
that focus on using donor tissue or the use or modification of a patient’s own cells or DNA 
instead of drugs, medical devices, or supplements).  
10 Id.  
11 See, e.g., Richard A. Epstein, The FDA’s Misguided Regulation of Stem-Cell 
Procedures: How Administrative Overreach Blocks Medical Innovation, MANHATTAN INST. 
(Sept. 24, 2013), https://www.manhattan-institute.org/html/fdas-misguided-regulation-
stem-cell-procedures-how-administrative-overreach-blocks-medical-5897 [https://perma.cc 
/JBW2-QFYJ]; James Gallagher, UK scientists edit DNA of human embryos, BBC (Sept. 20, 
2017), http://www.bbc.com/news/health-41269200 [https://perma.cc/8VWT-SM3C]; 
Maryn McKenna, Swapping Germs: Should Fecal Transplants Become Routine for 
Debilitating Diarrhea?, SCI. AM. (Dec. 1, 2011), https://www.scientificamerican.com/article 
/swapping-germs/ [https://perma.cc/9CCC-5W6B]. See infra Part I for more detail and 
descriptions of innovative medical technologies.  
12 McKenna, supra note 11 (noting that clinical trials involving fecal transplants were 
underway in Canada, but not the United States); See FDA Regulation of Human Cells, 
Tissues, and Cellular and Tissue-Based Products (HCT/P’s) Product List, U.S. FOOD & 
DRUG ADMIN., http://www.fda.gov/BiologicsBloodVaccines/TissueTissueProducts/Regulat 
ionofTissues/ucm150485.htm [https://perma.cc/G4FG-BAKG] (last updated Feb. 2, 2018) 
(listing “. . . cell nuclei, oocyte nuclei, mitochondrial genetic material in ooplasm, [and] 
genetic material contained in a genetic vector” as products that are regulated under “Section 
351 of the [Public Health Service] Act and/or the [Food, Drug & Cosmetic] Act” without 
explaining how the communicable disease provision of the Public Health Service Act 
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The FDA is using a regulatory framework that was created for drugs to regulate 
the practice of medicine.13 While the practice of medicine is subject to the state 
police power, the FDA has been continually encroaching on the practice of medicine 
by effectively banning new medical techniques through agency-issued letters or by 
pursuing litigation against physicians based on an over-expansive view of 
“commerce.”14 When doing so, the FDA often states that these techniques are within 
the FDA’s jurisdiction or “regulatory authority,” without explaining how the FDA 
has jurisdiction over these medical techniques or how political motivations may be 
affecting the agency’s decision-making.15 The FDA impedes the use of innovative 
                                               
“and/or” the Food, Drug, and Cosmetic Act applies to these “products.”); infra note 132 
(providing text from the FDA’s response to FOIA Request 2016-4882 and the associated 
shareholder lawsuit that highlighted the FDA’s actions.); see also Ariana Eunjung Cha, FDA 
cracks down on company marketing ‘three-parent’ babies, WASH. POST (Aug. 8, 2017), 
https://www.washingtonpost.com/news/to-your-health/wp/2017/08/07/fda-cracks-down-
on-company-marketing-three-parent-babies/?utm_term=.0562ad833f54 [https://perma.cc/ 
9GYZ-3HMQ] (citing Letter from Mary A. Malarkey, Director of Compliance and Biologics 
Quality, Center for Biologics Evaluation and Research, to Dr. John Zhang, CEO, Darwin 
Life, Inc. and New Hope Fertility Center (Aug. 4, 2017) (on file at the Washington Post)) 
(noting that not only does the FDA state that an investigational new drug application is 
required for techniques such as Dr. Zhang’s (a type of mitochondrial transfer), but such an 
attempt to obtain a pre-investigational new drug application would not be successful due to 
a federal appropriations rider); discussion infra Part II.B.2.b of fecal transplants with an 
emphasis on those patients who are driven to pursue “Do-it-yourself” fecal transplants; 
discussion infra Part III. 
13 See generally Myrisha S. Lewis, How Subterranean Regulation Hinders Innovation 
in Assisted Reproductive Technology, 39 CARDOZO L. REV. 1239 (2018) (providing more 
information on the process through which the FDA regulates such innovative medical 
treatments (with an emphasis on those that implicate fraught ethical areas)). In this article, 
after submitting Freedom of Information Act (FOIA) requests and examining primary source 
documents, I observed that the FDA has been consistently regulating forms of assisted 
reproductive technology that involve genetic modifications in a “subterranean” manner that 
effectively prevents their use in the United States. “Subterranean regulation” generally has 
four qualities: (1) contested agency jurisdiction; (2) the assertion of wrongdoing in an 
atypical manner; (3) obfuscation of the agency’s action, by not including addressees or all 
correspondence in publicly available databases (or FOIA requests); and (4) chilling effects 
on research. The term “subterranean” refers to the fact that the FDA’s jurisdiction over these 
techniques is questionable and also that the agency uses non-legislative rules, specifically 
letters sent on agency letterhead, to inform physicians that if they continue using those 
techniques, that they must participate in the agency’s new drug approval process; these letters 
have a chilling effect on research as physicians stop providing these techniques to patients 
after receiving these letters from the FDA, with one physician explaining that he felt 
“threatened” after receiving the letter. 
14 See Gonzales v. Oregon, 546 U.S. 243, 270 (2006) (discussing the state’s historic 
police power over the practice of medicine); See also infra Section II.B.2.c for discussion of 
the U.S. v. Regenerative Sciences litigation and the FDA’s use of subterranean regulation to 
target forms of assisted reproductive technology involving genetic modifications.  
15 See infra Section II.B.2.c for discussion of the U.S. v. Regenerative Sciences 
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medical technologies, in spite of the existence of laws that already protect patients, 
medical promise, and, in the case of at least one technique, the recommendations of 
the National Academies of Sciences, Engineering, and Medicine (National 
Academies).16 In this way, contrary to the prevalent belief that increased FDA 
regulation improves patient health, the administrative state is halting the use of these 
innovations in medical treatment to the potential detriment of patient care.17  
In spite of Executive Branch statements and the recent passage of legislation 
encouraging medical innovation, the current regulatory framework not only 
infringes on state jurisdiction over the practice of medicine but also uses a process 
that is not structured to regulate the life sciences.18 This Article argues that the 
current federal regulatory scheme actually has the effect of hindering innovation in 
the life sciences. The current federal regulatory scheme has this effect for at least 
two reasons. First, even with the passage of the 21st Century Cures Act, the current 
federal regulatory regime does not permit the FDA to exert such extensive 
jurisdiction—as the FDA now does—over the regulation of the life sciences.19  
Furthermore, the nature of life sciences innovations and their clinical use actually 
renders state regulation a critical piece of the regulatory puzzle as these innovations 
implicate the practice of medicine which is an area subject to the state’s historic 
police powers.20 Additionally, the federal regulatory scheme is not structured to 
regulate the life sciences, as evidenced by its historical roots and the manner in 
which the FDA has constructed an ad hoc regime to regulate such innovations over 
at least the past twenty years.21  
This Article’s main claim is that the FDA should not be regulating innovative 
new medical techniques in the current manner. Instead, the life sciences can only be 
adequately regulated through a regulatory scheme that is specifically created for 
                                               
litigation.  
16 See THE NAT’L ACADS. OF SCIS., ENG’G, & MED., MITOCHONDRIAL REPLACEMENT 
TECHNIQUES: ETHICAL, SOCIAL, AND POLICY CONSIDERATIONS (ANNE CLAIBORNE ET AL., 
2016). In the foregoing report, the Committee on the Ethical and Social Policy 
Considerations of Novel Techniques for Prevention of Maternal Transmission of 
Mitochondrial DNA Diseases provided a limited recommendation for the use of 
mitochondrial transfer in the United States. Id. at xv. The Committee was assembled at the 
request of the FDA and the National Academies of Sciences, Engineering, and Medicine. Id. 
at xiii. 
17 See, e.g., DANIEL CARPENTER, REPUTATION AND POWER: ORGANIZATIONAL IMAGE 
AND PHARMACEUTICAL REGULATION 1–2 (2010); see also infra Parts II and III.  
18 See Remarks by the President, supra note 7 and accompanying text; see also KEAN 
BIRCH, INNOVATION, REGIONAL DEVELOPMENT AND THE LIFE SCIENCES: BEYOND 
CLUSTERS 7 (2016) (discussing the definition of “life sciences”). 
19 See infra Part II.B.2 (discussing how the FDA regulates innovations in the life 
sciences even though those innovations do not fall wholly within federal jurisdiction).  
20 See Gonzales v. Oregon, 546 U.S. 243, 270 (2006) (discussing the state’s historic 
police power over the practice of medicine). 
21 See generally Lewis, supra note 13 (explaining how the FDA has exerted jurisdiction 
over human cellular and tissue-based products on an ad hoc basis). 
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them and that involves a greater role for state governments.22 This Article makes 
several contributions to the literature. First, the health law (and the life sciences) 
legal literature is marked by fragmentation.23 This Article takes a synthetic approach 
by examining multiple agency targets in one article.24 Furthermore, often these 
agency targets are the subject of separate legal disciplines. For example, articles 
focused on intellectual property tend to focus on CRISPR-Cas9 and gene editing; 
articles from the family law discipline focus on assisted reproductive technology 
(ART); articles categorized as health law consider innovations in insurance markets; 
and administrative law scholarship focuses on the use of non-legislative rules.25 This 
Article contributes to the literature by revealing a common problem: the FDA’s 
regulation of products that are likely outside of its jurisdiction.26 Moreover, this 
                                               
22 State governments have experience encouraging innovation in the life sciences. See, 
e.g., CAL. INST. FOR REGENERATIVE MED., CIRM STRATEGIC PLAN: 2016 AND BEYOND 4, 
https://www.cirm.ca.gov/sites/default/files/CIRM_StrategicPlan_2016.pdf [https://perma.cc 
/4NJP-DFX5] (last visited June 10, 2018) [hereinafter CIRM STRATEGIC PLAN] (noting that 
“[o]n November 2, 2004, 59% of the voters approved Proposition 71, which amended the 
California Constitution to establish the right to conduct stem cell research in California and 
authorize[d] $3 billion to fund stem cell research.”). 
23 Lawrence A. Gostin, Scott Burris & Zita Lazzarini, The Law and the Public’s Health: 
A Study of Infectious Disease Law in the United States, 99 COLUM. L. REV. 59, 118 (1999) 
(“Our review of public health legislation suggests that state public health law remains 
fragmented both within and among states.”); see also Mark A. Hall, Law, Medicine, and 
Trust, 55 STAN. L. REV. 463, 464 (2002) (“Scholars have long noted that the field of health 
care law lacks cohesion. They speak in terms of the ‘pathologies’ of health law, or its 
contradictory and competing ‘paradigms,’ which constitute a ‘chaotic, dysfunctional 
patchwork.’ This conceptual disarray exists because, unlike other areas of law, no unifying 
principle or animating concern has yet been identified for the law of health care delivery. For 
example, family law is concerned with rights and obligations arising from intimate 
relationships, environmental law is built around a set of core statutes, and intellectual 
property law applies general property principles to intangible constructs. The field of health 
care law, in contrast, is largely a creature of happenstance.” (citations omitted)).  
24 Many scholars have written analyses of specific, individual areas in which the FDA 
is hindering medical innovation. For example, other scholars have written articles that focus 
on the FDA’s questionable jurisdiction over other innovative techniques such as the use of 
autologous stem cells as an alternative to orthopedic surgery and heart surgery. See, e.g., 
Epstein, supra note 11; see also Lewis, supra note 13.  
25 See, e.g., Jorge L. Contreras & Jacob S. Sherkow, CRISPR, Surrogate Licensing, and 
Scientific Discovery, 355 SCIENCE 698, 698 (2017); Abbe R. Gluck, Federalism from 
Federal Statutes: Health Reform, Medicaid, and the Old-Fashioned Federalists’ Gamble, 81 
FORDHAM L. REV. 1749, 1749–51 (2013); Nicole Huberfeld, Federalizing Medicaid, 14 U. 
PA. J. CONST. L. 431, 435–36 (2011); John F. Manning, Non-legislative Rules, 72 GEO. 
WASH. L. REV. 893, 893 (2004); Radikha Rao, Assisted Reproductive Technology and the 
Threat to the Traditional Family, 47 HASTINGS L.J. 951, 952 (1996); John A. Robertson, 
Assisted Reproductive Technology and the Family, 47 HASTINGS L.J. 911, 913 (1996); Mark 
Seidenfeld, Substituting Substantive for Procedural Review of Guidance Documents, 90 
TEX. L. REV. 331, 333 (2011). 
26 See infra Part II.A (providing the definitions of the terms “biologics” and “drugs” in 
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jurisdictional overreaching corresponds to an over-regulation that will continue to 
pose a barrier to the clinical use of innovative procedures. Additionally, this Article 
examines newer fields that have been the subject of less attention in the legal 
literature such as fecal microbiota transplants.27 The Article also reveals that while 
regulatory capture has been a criticism of the FDA’s relationship with the 
pharmaceutical industry in the past, recent medical innovations exist in a regulatory 
space that is both outside of the pharmaceutical industry and less amenable to 
regulatory capture.28 
This Article proceeds in four Parts. Part I provides an overview of innovative 
medical techniques that are currently being regulated by the FDA including 
techniques of ART involving the use of donor material in order to prevent the 
transmission of harmful genetic diseases to offspring, gene editing, methods of ART 
that use a woman’s own cells, fecal microbiota transplants, and autologous stem cell 
treatments. Part II begins with the National Academies’ observation that many new 
biotechnological innovations do not fall within federal jurisdiction and then 
examines the tension between the federal administrative state and the practice of 
medicine. This Article specifically addresses what the 2017 National Academies’ 
report did not: jurisdictional gaps that do not permit the FDA to regulate many of 
the innovative medical techniques discussed in Part I.29 Part III of the Article 
examines the broader implications of the agency’s regulatory actions including how 
federal interference has hindered innovation without adequate statutory 
authorization. Part III also explains why the current ad hoc federal regime is not only 
                                               
the context of FDA regulation). 
27 See infra Part II.B.2.b (noting that physicians must rely on promises from the FDA 
to exercise its enforcement discretion in favor of those physicians, in the context of fecal 
microbiota transplants, which leads to an unpredictable legal situation); see, e.g., FMT 
demonstrates consistently high success rates for recurrent CDI, MAYO CLINIC, 
http://www.mayoclinic.org/medical-professionals/clinical-updates/digestive-diseases/fmt-
demonstrates-consistently-high-success-rates-for-recurrent-cdi [https://perma.cc/Q6VG-
TW89] (last visited June 10, 2018) (“Maria I. Vazquez Roque, M.D., a gastroenterologist at 
Mayo Clinic’s campus in Jacksonville, Florida, observes that the Food and Drug 
Administration (FDA) initially proposed requiring investigational new drug (IND) status for 
FMT procedures. That stance would have denied access to the procedure for many, if not 
most, patients and was later changed. For the time being, the FDA exercises enforced 
discretion.”). A Westlaw search of “fecal/p transplant” revealed 9 articles in the Journals and 
Law Review Search Engine as of February 13, 2018. But see Rachel E. Sachs & Carolyn A. 
Edelstein, Ensuring the safe and effective FDA regulation of fecal microbiota 
transplantation, 2 J.L. & BIOSCIENCES 396, 396 (2015) (“. . . examin[ing] the nature of the 
regulatory challenges the FDA will face in deciding to regulate [fecal microbiota 
transplantation] as a biologic drug . . .”).  
28 See Nicholas Bagley & Richard L. Revesz, Centralized Oversight of the Regulatory 
State, 106 COLUM. L. REV. 1260, 1289 (2006) (observing that the “FDA has recently been 
the subject of searing criticism because of its cozy relationship with the pharmaceutical 
industry” (citation omitted)).  
29 See discussion infra Part II. 
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inapplicable to the life sciences but also not structured to regulate the life sciences.30 
After explaining why states actually retain jurisdiction over a critical aspect of life 
sciences regulation, Part IV proposes several ways in which life sciences regulation 
could be improved with an emphasis on methods that would emphasize the increased 
regulatory involvement of individual states. The Article then concludes.  
 
I.  SCIENTIFIC BACKGROUND ON INNOVATIVE MEDICAL TECHNIQUES 
 
While the term “life sciences” traditionally has “refer[red] to biomedical 
research and innovation,” many techniques that compose the “innovation” part of 
the life sciences definition are a part of medical practice as opposed to discoveries 
resulting from laboratory research.31 The case studies in this Part emphasize 
innovations in the life sciences that use the human body in order to treat ailments.  
 
A.  Genetic Modifications of the Human Body: Mitochondrial Transfer, 
CRISPR-Cas9, Gene Editing, and Cloning 
 
With the addition of genetic modifications, ART has moved from being an area 
of state regulation and experimentation to an area of federal regulation, which entails 
additional regulatory barriers.32 For example, using ART that involves genetic 
modifications has been prevented by the exercise of FDA power through non-
legislative rules.33 While ART techniques were originally used to treat infertile 
couples, a new form of ART, mitochondrial transfer, has received significant 
attention recently due to its ability to prevent the transmission of harmful genetic 
                                               
30 See THE NAT’L ACADS. OF SCIS., ENG’G, & MED., PREPARING FOR FUTURE 
PRODUCTS OF BIOTECHNOLOGY 10 (2017), http://www.nap.edu/24605 [https://perma.cc/EQ 
N6-PYWF]. 
31 BIRCH, supra note 18.  
32 See  e.g.,  Michele Goodwin, A View from the Cradle: Tort Law and the Private 
Regulation of Assisted Reproduction, 59 EMORY L.J. 1039, 1071–72, 1079 (2010) 
(discussing the state-based regulation of assisted reproductive technology and the lack of 
federal oversight over “traditional” forms of assisted reproductive technology such as 
artificial insemination and in vitro fertilization not involving genetic modification); see 
generally CHARLES P. KINDREGAN, JR. & MAUREEN MCBRIEN, ASSISTED REPRODUCTIVE 
TECHNOLOGY: A LAWYER’S GUIDE TO EMERGING LAW AND SCIENCE (2d ed. 2011) 
(discussing the state-by-state regulation of assisted reproductive technology). 
33 See infra Part II.B; see, e.g., Advisory on Legal Restrictions on the Use of 
Mitochondrial Replacement Techniques to Introduce Donor Mitochondria into Reproductive 
Cells Intended for Transfer into a Human Recipient, U.S. FOOD & DRUG ADMIN. (Aug. 4, 
2017), https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ucm57 
0185.htm [https://perma.cc/4FQA-SYWS] [hereinafter Restrictions on Mitochondrial 
Replacement Techniques]. 
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diseases from parents to their children.34 Mitochondria provide energy to the cell; 
however, the inheritance of defective mitochondria can cause genetic disease.35  
Mitochondrial transfer is a form of ART that combines in vitro fertilization and 
genetic modification to prevent the transmission of harmful genetic disease.36 
Clinical trials are underway in the United Kingdom where the “Newcastle Group” 
(as the scientists who developed the technique are called)  
 
uses a modified version of [in vitro fertilization] to combine the healthy 
mitochondria of a donor woman with DNA of the two parents.37  
It results in babies with 0.1% of their DNA from the second woman 
and is a permanent change that would echo down through the 
generations.38  
 
An American scientist, Dr. Shoukhrat Mitalipov, has also pioneered a 
mitochondrial transfer technique; however, as discussed infra in Parts II and III, 
while human clinical trials go forward in the United Kingdom, mitochondrial 
transfer has been subjected to burdensome regulatory requirements and a 
congressional funding restriction in the United States.39  
Similarly, Autologous Germline Mitochondrial Energy Transfer (AUGMENT) 
is another technique that has rarely been explored in the legal literature.40 
AUGMENT is another technique that uses the human body to address infertility; 
however, due to the FDA’s use of regulatory tools, as explored in Part II, this 
                                               
34 See, e.g., Paula Amato, et. al., Three-Parent IVF: Gene Replacement for the 
Prevention of Inherited Mitochondrial Diseases, 101 FERTILITY AND STERILITY 31 (2014); 
see also Letter to Sponsors / Researchers - Human Cells Used in Therapy Involving the 
Transfer of Genetic Material By Means Other than the Union of Gamete Nuclei, U.S. FOOD 
& DRUG ADMIN. (Jul. 6, 2001), https://wayback.archive-it.org/7993/20170404210748/https: 
//www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm105852.htm [https://perma. 
cc/978M-BZCN] [hereinafter Human Cells Used in Therapy]. 
35 See, e.g., James Gallagher, UK Approves Three-Person Babies, BBC (Feb. 24, 2015), 
http://www.bbc.com/news/health-31594856 [https://perma.cc/TY6V-W4AG]; see also 
Marni J. Falk et al., Mitochondrial Replacement Techniques — Implications for the Clinical 
Community, 374 NEW ENG. J. MED. 1103, 1103 (2016) (“[P]ersons [affected with 
mitochondrial disease] may present at any age with some combination of severe, often 
progressive, and sometimes fatal neurologic, musculoskeletal, cardiac, gastrointestinal, 
renal, ophthalmologic, and audiologic involvement. No cures or therapies have been 
approved by the Food and Drug Administration (FDA) for any [mitochondrial] DNA disease, 
although symptom-based clinical management can be beneficial.”).  
36 See supra note 35.   
37 James Gallagher, UK Approves Three-Person Babies, BBC (Feb. 24, 2015), 
http://www.bbc.com/news/health-31594856 [https://perma.cc/TY6V-W4AG]. 
38 Id. 
39 See discussion infra Part II.B.2.a, Part III.A. 
40 See Karen Weintraub, Rejuvenating the Chance of Motherhood?, MIT TECH. REV. 
(Dec. 9, 2016), https://www.technologyreview.com/s/603065/rejuvenating-the-chance-of-
motherhood/ [https://perma.cc/NY8U-DWVE].  
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treatment—created by an American company—“is so far available only in Canada 
and Japan . . . .”41 Genome- or gene-editing technologies  
 
allow genetic material to be added, removed, or altered at particular 
locations in the genome. Several approaches to genome editing have been 
developed. A recent one is known as CRISPR-Cas9, which is short for 
clustered regularly interspaced short palindromic repeats and CRISPR-
associated protein 9. The CRISPR-Cas9 system has generated a lot of 
excitement in the scientific community because it is faster, cheaper, more 
accurate, and more efficient than other existing genome editing methods.42 
 
Human reproductive cloning, as opposed to cloning for human research, is a 
“process[] that can be used to produce genetically identical copies of a biological 
entity. The copied material, which has the same genetic makeup as the original, is 
referred to as a clone.”43 Human reproductive cloning is not currently a medical 
treatment; however, it is briefly mentioned because the method that the federal 
government has used to regulate it is similar to that used to regulate innovative 
medical techniques as noted infra in Part II.44 
 
B.  Fecal Microbiota Transplants 
 
Fecal transplants have received an increasing amount of medical and media 
attention lately; yet, the subject has been largely neglected by the legal literature.45 
                                               
41 Id.  
42 See What Are Genome Editing and CRISPR-Cas9?, NAT’L INSTS. OF HEALTH (Jan. 
16, 2018), https://ghr.nlm.nih.gov/primer/genomicresearch/genomeediting [https://perma.cc 
/NYY4-RB5B].  
43 Cloning, NAT’L INSTS. OF HEALTH (Mar. 21, 2017), https://www.genome.gov/2502 
0028/cloning-fact-sheet/ [https://perma.cc/QH4Q-3QEA] (“The term cloning describes a 
number of different processes that can be used to produce genetically identical copies of a 
biological entity. The copied material, which has the same genetic makeup as the original, is 
referred to as a clone.”). 
44 See, e.g., Gail H. Javitt & Kathy Hudson, Regulating (for the Benefit of) Future 
Persons: A Different Perspective on the FDA’s Jurisdiction to Regulate Human 
Reproductive Cloning, 2003 UTAH L. REV. 1201, 1207–08 (2003) (“CBER’s claim that 
reproductive cloning is not reproduction, along with its failure to identify the component of 
cloning that constitutes a drug, underscores the fact that the FDA has, in all of its iterations 
of what might be termed policy, assiduously avoided answering the central question of what 
precisely is the subject of its jurisdiction, or, in statutory parlance, the article that it seeks to 
regulate . . . Thus far, the FDA appears to be floundering for a regulatory hook; it is positing 
a desired regulatory result that is in search of a cogent legal theory.”).  
45 See supra note 27 and accompanying text; see also Ciaran P. Kelly, Fecal Microbiota 
Transplantation — An Old Therapy Comes of Age, 368 N. ENGL. J. MED. 474, 474–75 
(2013); David Salisbury, These days, fecal transplantation is no joke, VANDERBILT UNIV. 
(July 12, 2016), https://news.vanderbilt.edu/2016/07/12/these-days-fecal-transplantation-is-
no-joke/ [https://perma.cc/7DC8-WCMB]; Carl Zimmer, Fecal Transplants can be Life-
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Fecal transplants can minimize patient suffering caused by certain medical 
conditions, especially drug-resistant infections of Clostridium difficile, commonly 
referred to as “C. diff,” which can be acquired during hospital stays, typically after 
use of antibiotic medication.46 “Fecal transplantation (or bacteriotherapy) is the 
transfer of stool from a healthy donor into the gastrointestinal tract for the purpose 
of treating recurrent C. difficile colitis” when antibiotics have proven ineffective.47 
A recent study showed that just one fecal transplant was 81% effective among those 
suffering from colitis caused by Clostridium difficile.48 As explained in Part II, infra, 
due to the FDA’s assertion of jurisdiction over this medical treatment, it is only 
available under very limited circumstances to patients in the United States.49  
 
C.  Stem Cell Treatments 
 
Stem cells have been a part of the American scientific, legal, and medical 
discourse since at least the 1960s.50 Stem cells are so versatile and varied that the 
                                               
Saving, but How?, N.Y. TIMES (July 15, 2016), https://www.nytimes.com/2016/07/15/ 
science/fecal-transplants-bacteria-viruses.html?mcubz=0&_r=0 [https://perma.cc/Q6EM-
F223].  
46 See, e.g., Fernanda C. Lessa et al., Burden of Clostridium difficile Infection in the 
United States, 372 N. ENG. J. MED. 825, 827 (2015) (“C. difficile has become the most 
common cause of health care–associated infections in U.S. hospitals, and the excess health 
care costs related to C. difficile infection are estimated to be as much as $4.8 billion for acute 
care facilities alone.” (citations omitted)); C. difficile infection, MAYO CLINIC, 
https://www.mayoclinic.org/diseases-conditions/c-difficile/symptoms-causes/syc-2035 
1691 [https://perma.cc/M45J-XSFJ]; FDA struggles to regulate fecal transplants, CBS 
NEWS (June 26, 2014), http://www.cbsnews.com/news/fda-struggles-to-regulate-fecal-
transplants/ [https://perma.cc/6JHP-5WD6] [hereinafter FDA struggles]; see also Kenneth 
A. Young, Of Poops and Parasites: Unethical FDA Overregulation, 69 FOOD & DRUG L.J. 
555, 562–63 (2014); How Doctors are Using Fecal Transplants to Treat Deadly Disease, 
VICE NEWS (June 22, 2016), https://www.vice.com/en_us/article/vice-on-hbo-student-debt-
fecal-transplant [https://perma.cc/6JHP-5WD6] [hereinafter Doctors Using Fecal 
Transplants]; Woo Jung Lee et. al, Fecal Microbiota Transplantation: A Review of Emerging 
Indications Beyond Relapsing Clostridium difficile Toxin Colitis, 11 GASTROENTEROLOGY 
& HEPATOLOGY 24, 25 (2015), available at https://www.ncbi.nlm.nih.gov/pmc/articles/PM 
C4836576/pdf/GH-11-24.pdf [https://perma.cc/2676-UN2F].  
47 Fecal Transplantation (Bacteriotherapy), JOHNS HOPKINS MED. 
https://www.hopkinsmedicine.org/gastroenterology_hepatology/clinical_services/advanced
_endoscopy/fecal_transplantation.html [https://perma.cc/V7Y2-UDJR] (last visited June 10, 
2018). 
48 See Andi L. Shane, The Problem of DIY Fecal Transplants THE ATLANTIC (Jul. 16, 
2013), https://www.theatlantic.com/health/archive/2013/07/the-problem-of-diy-fecal-
transplants/277813/ [https://perma.cc/87A4-BPM7]; Hyun Choi & Young-Seok Cho, Fecal 
Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives, 
49 CLIN. ENDOSC. 257, 258 (2016). 
49 See infra Part II.B.2.b. 
50 See, e.g., Leonardo M. R. Ferreira, Stem Cells: A Brief History and Outlook, HARV. 
(Jan. 2, 2014), http://sitn.hms.harvard.edu/flash/2014/stem-cells-a-brief-history-and-
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possibilities surrounding their use have been characterized as “endless.”51 Unlike 
with fecal transplants, which involve the use of a donor’s material, autologous stem 
cell treatments use an individual’s own tissue.52 While “stem cells” in general have 
received significant media treatment, not all stem cells are the same and often the 
public discourse does not acknowledge this difference.53 Autologous stem cells, as 
opposed to allogeneic stem cells, are stem cells that come from a patient’s own 
body.54 The medical promise of stem cells has been discussed for years, with 
discussion moving from the topic of embryonic stem cells (and associated discourse 
which often includes a political discussion of abortion) to that of adult stem cells.55 
Adult stem cells are also referred to as “autologous stem cells” and have been used 
as an alternative to knee replacements, to treat cardiac conditions, and to alleviate 
the symptoms of Parkinson’s disease.56  
 
* * * 
 
The techniques examined in this Part are all innovative medical treatments that 
tackle medical ailments in different ways. Even though some of these techniques use 
the material of a donor, whereas others use a patient’s own cells to tackle ailments 
that pharmaceuticals and medical devices have been unable to resolve successfully, 
these innovative techniques should all be studied together because their clinical use 
faces a common challenge: FDA regulatory hurdles. The techniques examined in 
this Part are all alike insofar as they are innovative medical treatments that hold great 
promise for patient health yet, as explained in the next Part, none of these techniques 
clearly fits within the categories of products whose regulation is statutorily assigned 
to the FDA.  
 
                                               
outlook-2/ [https://perma.cc/3GVV-KYZC]. 
51 See Coaxing Cells, JOHNS HOPKINS MED. http://www.hopkinsmedicine.org/stem_ 
cell_research/coaxing_cells/index.html [https://perma.cc/P6DZ-P6EJ] (last visited June 10, 
2018). 
52 See NAT’L INSTS. OF HEALTH, Hematopoietic Stem Cells, in STEM CELLS: SCIENTIFIC 
PROGRESS AND FUTURE RESEARCH DIRECTIONS 46 (2001), https://stemcells.nih.gov/info/ 
2001report/chapter5.htm [https://perma.cc/MU4W-YPDJ]. 
53 See, e.g., Stem Cell Basics III: What are embryonic stem cells?, NAT’L INSTS. OF 
HEALTH, https://stemcells.nih.gov/info/basics/3.htm [https://perma.cc/JA9E-Y3TB] (last 
visited June 10, 2018); Stem Cell Basics I: Introduction: What are stem cells, and why are 
they important?, NAT’L INSTS. OF HEALTH, https://stemcells.nih.gov/info/basics/1.htm 
[https://perma.cc/992F-7LP8] (last visited December 3, 2018). Much of the controversy over 
stem cells stems from discussions of research on embryonic stem cells. Stem Cells Fast 
Facts, CNN (July 17, 2018, 4:36 PM), http://www.cnn.com/2013/07/05/health/stem-cells-
fast-facts/index.html [https://perma.cc/CZJ8-M355].  
54 Supra note 53. 
55 Id.  
56 See Epstein, supra note 11; infra Part II.B.2.c 
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II.  THE TENSION BETWEEN THE ADMINISTRATIVE STATE AND THE PRACTICE  
OF MEDICINE 
 
Biotechnology specifically presents a challenge for regulation because, as 
stated by the National Academies in a 2017 report, Preparing for the Future 
Products of Biotechnology, there are several aspects of biotechnology that do not 
fall within the current purview of federal jurisdiction.57 There are limits to this 2017 
National Academies report; for example, human drugs and medical devices were 
specifically excluded from the study at a “sponsor’s request.”58 While the report did 
not identify who that sponsor was, presumably, the sponsor was the FDA who was 
a sponsor of the 2017 report and is also the only agency that would regulate drugs 
and medical devices intended for human use.59 As noted in the Introduction, this 
Article specifically addresses what the 2017 National Academies’ report did not. As 
this Part will show, when jurisdictional “gaps” occur, as they do in the regulatory 
space surrounding innovative treatments in the life sciences, the FDA often asserts 
jurisdiction and regulates that area anyway, even in the absence of statutory 
authorization.  
This Part provides background on the intersection between federal statutory 
law, federal agency regulations, and the regulation of innovations in the life sciences. 
Current regulatory practices have created a tension between federal regulation and 
state jurisdiction.60 That tension, more specifically, is one between state jurisdiction 
over the practice of medicine and the FDA’s continued usurpation of that state 
jurisdiction, which it does by regulating in areas outside of its jurisdiction. This Part 
explains how the FDA’s approach to these treatments that use the human body to 
treat illness, instead of traditional “drugs” or other “articles” is to expand federal 
jurisdiction over the human body, without statutory authorization, often to the 
detriment of innovation. There is also a tension between innovation and regulation 
that the FDA resolves by using a heavy-handed, risk-averse approach as opposed to 
one that balances jurisdictions and aims to increase the availability of life-saving 
treatments.  
  
                                               
57 See THE NAT’L ACADS. OF SCIS., ENG’G, & MED., PREPARING FOR FUTURE 
PRODUCTS OF BIOTECHNOLOGY 10 (2017), available at http://www.nap.edu/24605 
[https://perma.cc/EQN6-PYWF].  
58 Id. at 2 (“Human drugs and medical devices will not be included in the purview of 
the study per a sponsor’s request.”).  
59 Id. at 17 (listing the U.S. Food and Drug Administration, U.S. Department of 
Agriculture, and U.S. Environmental Protection Agency as the sponsors of the report).   
60 See Lewis, supra note 13, at 1252.  
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A.  Definitional Background 
 
1.  The Practice of Medicine, Research, and Innovation  
 
While the pharmaceutical industry is clearly within the FDA’s jurisdiction, 
medicine is not. As noted earlier, the practice of medicine is regulated by states.61 
As indicated by the Supreme Court’s ruling in Gonzales v. Oregon, for example, the 
federal government does have a role to play in affecting the practice of medicine as, 
for example, physicians have to obtain clearance through the Drug Enforcement 
Administration to prescribe certain drugs (that have been approved by the FDA).62 
However, there are limits to the federal government’s jurisdiction over the practice 
of medicine as the federal government cannot, for example, criminalize the actions 
of physicians who aid in state-approved, physician-assisted suicide because the U.S. 
Attorney General does not approve of such a regime.63 In other words, there is some 
overlap between the practice of medicine and articles that are regulated by the 
federal government, including controlled substances and pharmaceuticals, but that 
overlap does not allow the federal government to regulate the practice of medicine.64  
The current FDA Commissioner (who previously worked at the FDA as Deputy 
Commissioner for Medical and Scientific Affairs), Scott Gottlieb, M.D.,65 criticized 
the FDA’s use of Risk Evaluation and Mitigation Strategies (REMS) to impose 
conditions on drug approvals (and ultimately physicians), while he was a Resident 
Fellow at the American Enterprise Institute.66 While criticizing the REMS process, 
Dr. Gottlieb observed: 
 
Too many of the [FDA]’s decisions and judgments are starting to turn on 
FDA’s desire to regulate aspects of the practice of medicine. The agency 
wants to make sure that doctors conform to the FDA’s judgment about 
how new products should be used. But FDA’s control over medical 
practice is tenuous, and will remain so . . . .  
. . . [The FDA’s] judgment should not stand in for the considerations 
that get made in real world medical practice, where doctors and patients 
                                               
61 See, e.g., Patricia J. Zettler, Pharmaceutical Federalism, 92 IND. L.J. 845, 885 (2017) 
(“Conventional wisdom in health law and policy holds that states regulate the practice of 
medicine, while the federal government—specifically the FDA—regulates drugs.”). 
62 Gonzales v. Oregon, 546 U.S. 243, 252 (2006). 
63 See Gonzales, 546 U.S. 243.  
64 Id. 
65 Meet Scott Gottlieb, M.D., Commissioner of Food and Drugs, U.S. FOOD & DRUG 
ADMIN. (May 11, 2017), https://www.fda.gov/aboutfda/centersoffices/ucm557569.htm 
[https://perma.cc/C85A-YD2Y] [hereinafter Meet Scott Gottlieb]. 
66 Scott Gottlieb, FDA Safety Regs Faulted for Lax Oversight, FORBES (Feb. 12, 2013, 
3:12 PM), https://www.forbes.com/sites/scottgottlieb/2013/02/13/fda-safety-regulations-
faulted-for-lax-oversight/#503be0a64004 [https://perma.cc/XT25-6WPC]. 
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have to balance difficult issues to tailor treatments to each person’s unique 
circumstances and needs.67 
 
Today, five years after that criticism, Dr. Gottlieb leads an agency that continues to 
use the previously criticized REMS process and continues to target innovative 
medical treatments for onerous legal treatment.68 
Contrary to the FDA’s regulatory position, using human tissue to treat patient 
ailments is properly categorized within the practice of medicine and not the 
regulation of drugs.69 Different states have different definitions of the practice of 
medicine; however, it is generally seen as “the art of healing.”70 Additionally, 
national standards of care exist in connection with medical malpractice and the 
licensing of physicians.71 Medical techniques are a part of the practice of medicine, 
while pharmaceuticals, biologics, and vaccines, for example, are tools that are used 
as a part of the practice of medicine.72 Thus, the FDA has jurisdiction over contact 
                                               
67 Id. But see Press Release, U.S. Food & Drug Admin., Statement from FDA 
Commissioner Scott Gottlieb, M.D. on new steps to improve FDA review of shared Risk 
Evaluation and Mitigation Strategies to improve generic drug access (Nov. 8, 2017), 
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm584259.htm 
[https://perma.cc/83LC-FKXM].  
68 Meet Scott Gottlieb, supra note 65 (“Dr. Scott Gottlieb was sworn in as the 23rd 
Commissioner of Food and Drugs on May 11, 2017.”); see Ariana Eunjung Cha, FDA Cracks 
Down on Company Marketing ‘Three-Parent’ Babies, WASH. POST (Aug. 8, 2017), 
https://www.washingtonpost.com/news/to-your-health/wp/2017/08/07/fda-cracks-down-
on-company-marketing-three-parent-babies/?utm_term=.0562ad833f54 [https://perma.cc/ 
9GYZ-3HMQ]; Letter from Mary A. Malarkey, Dir. of Office of Compliance & Biologics 
Quality, U.S. Food & Drug Admin., to John Zhang, PhD, MD, Chief Exec. Officer, Darwin 
Life, Inc. & New Hope Fertility Ctr. (Aug. 4, 2017), https://www.fda.gov/downloads/Bio 
logicsBloodVaccines/GuidanceComplianceRegulatoryInformation/ComplianceActivities/E
nforcement/UntitledLetters/UCM570225.pdf [https://perma.cc/M28W-C4ST].  
69 For the FDA’s regulatory position, see for example Human Cells Used in Therapy, 
supra note 34. 
70 See JAMA 100 Years Ago: What Constitutes the Practice of Medicine?, 299 J. AMER. 
MED. ASS’N 463 (reprinted Jan. 30, 2008); see also Patricia J. Zettler, Toward Coherent 
Federal Oversight of Medicine, 52 SAN DIEGO L. REV. 427, 435–36, 451 (2015).  
71 See, e.g., Nicole Huberfeld, Federalizing Medicaid, 14 U. PA. J. CONST. L. 431, 476–
79 (2011). 
72 See, e.g., Pharmaceutical products, WHO, http://www.who.int/topics/pharmaceut 
ical_products/en/ [https://perma.cc/85RU-UQRQ] (last visited June 10, 2018) 
(“Pharmaceutical products—more commonly known as medicines or drugs—are a 
fundamental component of both modern and traditional medicine. It is essential that such 
products are safe, effective, and of good quality, and are prescribed and used rationally.”); 
see also FDA’s Role in Regulating Medical Devices, U.S. FOOD & DRUG ADMIN.,  
https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/HomeHealthandCon
sumer/HomeUseDevices/ucm204884.htm [https://perma.cc/Q2K5-N7W2] (last visited June 
10, 2018); see also What does FDA regulate?, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/AboutFDA/Transparency/Basics/ucm194879.htm [https://perma.cc/ 
N7RE-LSFE] (last visited June 10, 2018).  
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lenses and LASIK surgery machines, but it does not have jurisdiction over LASIK 
surgery itself, other surgical techniques, or the licensing of ophthalmologists.73 
Just as the line between medical practice and the tools used to practice medicine 
is blurring, the line between research and clinical innovation has been hazy for some 
time. Nonetheless, it is a significant line as it marks a limit between federal and state 
regulatory authority. The federal “Common Rule,” which is “heavily influenced by 
the Belmont Report, written in 1979 by the National Commission for the Protection 
of Human Subjects of Biomedical and Behavioral Research,” is a part of the legal 
foundation of the FDA’s jurisdiction over research.74 The term “Common Rule” is 
a term that refers to a number of regulations promulgated by the U.S. Department of 
Health and Human Services that address human subjects research.75 However, the 
federal government does not have regulatory authority over all research. Instead, the 
federal government’s authority over research is limited to categories such as 
research “conducted or supported by a federal department or agency” and 
“[r]esearch subject to regulation,” which includes research for which the 
government “has specific responsibility.”76 Thus, the example offered in the 
regulations of “[r]esearch subject to regulation” is “Investigational New Drug 
requirements administered by the Food and Drug Administration” as those 
submitting applications for marketing approval from the FDA have to adhere to 
                                               
73 See, e.g., LASIK: FDA’s Role, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/SurgeryandLifeSupp
ort/LASIK/ucm061319.htm [https://perma.cc/XM5F-E2N7] (last visited June 10, 2018) 
(“FDA regulates the sale of medical devices in the U.S. and monitors the safety of all 
regulated medical devices. In the U.S., FDA regulates the sale of medical devices such as 
the lasers used for LASIK. Before a medical device can be legally sold in the U.S., the person 
or company that wants to sell the device must seek approval from the FDA. To gain approval, 
they must present evidence that the device is reasonably safe and effective for a particular 
use. 
The FDA does not have the authority to: 
• Regulate a doctor’s practice. In other words, FDA does not tell doctors what 
to do when running their business or what they can or cannot tell their 
patients. 
• Set the amount a doctor can charge for LASIK eye surgery. 
• “Insist” the patient information booklet from the laser manufacturer be 
provided to the potential patient. 
• Make recommendations for individual doctors, clinics, or eye centers. FDA 
does not maintain nor have access to any such list of doctors performing 
LASIK eye surgery. 
• Conduct or provide a rating system on any medical device it regulates.”). 
74 Federal Policy for the Protection of Human Subjects (‘Common Rule’), U.S. DEP’T 
HEALTH & HUM. SERVS. (Mar. 18, 2016), https://www.hhs.gov/ohrp/regulations-and-
policy/regulations/common-rule/index.html [https://perma.cc/4LVY-KQ2E].  
75 Id. 
76 45 C.F.R. §§ 46.101(a), 46.102(e) (2009). For more on the limits on the federal 
government’s ability to regulate research, see BARRY R. FURROW ET AL., HEALTH LAW: 
CASES, MATERIALS AND PROBLEMS 1746–56 (7th ed. 2013). 
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those requirements.77 Beyond that, “research” is defined by the U.S. Department of 
Health and Human Services (which contains the FDA) as “a systematic 
investigation, including research development, testing and evaluation, designed to 
develop or contribute to generalizable knowledge.”78  
Furthermore, physician efforts to aid one patient, as opposed to an investigation 
to aid many, are classified as “clinical innovation” or “practice” as opposed to 
human research or experimentation.79 The term “medical practice” is a part of the 
states’ historic “police powers to legislate as to the protection of the lives, limbs, 
health, comfort, and quiet of all persons.”80 The Belmont Report, for example, when 
distinguishing between medical practice and medical research, noted:  
 
For the most part, the term “practice” refers to interventions that are 
designed solely to enhance the well-being of an individual patient or client 
and that have a reasonable expectation of success. The purpose of medical 
or behavioral practice is to provide diagnosis, preventive treatment or 
therapy to particular individuals. By contrast, the term “research[”] 
designates an activity designed to test an hypothesis, permit conclusions 
to be drawn, and thereby to develop or contribute to generalizable 
knowledge (expressed, for example, in theories, principles, and statements 
of relationships) . . . . 
When a clinician departs in a significant way from standard or 
accepted practice, the innovation does not, in and of itself, constitute 
research. The fact that a procedure is “experimental,” in the sense of new, 
untested or different, does not automatically place it in the category of 
research. Radically new procedures of this description should, however, 
be made the object of formal research at an early stage in order to 
determine whether they are safe and effective. Thus, it is the responsibility 
                                               
77 45 C.F.R. § 46.102(e). 
78 45 C.F.R. § 46.102(d). The U.S. Food and Drug Administration is a part of the U.S. 
Department of Health and Human Services. See Food and Drug Administration, U.S. DEP’T 
OF HEALTH & HUM. SERVS., (Mar. 18, 2016), https://www.hhs.gov/ohrp/regulations-and-
policy/regulations/fda/index.html [https://perma.cc/9QTK-CC34] (“The Food and Drug 
Administration (FDA) is an HHS agency that regulates clinical investigations of products 
under its jurisdiction, such as drugs, biological products, and medical devices.”).  
79 See, e.g., Nancy M. P. King, The Line Between Clinical Innovation and Human 
Experimentation, 32 SETON HALL L. REV. 573, 573–74 (2002); see also U.S. DEP’T OF 
HEALTH & HUMAN SERVS., BELMONT REPORT: ETHICAL PRINCIPLES AND GUIDELINES FOR 
PROTECTION OF HUMAN SUBJECTS OF RESEARCH (1979), https://www.hhs.gov/ohrp/regulat 
ions-and-policy/belmont-report/index.html [https://perma.cc/K55Q-AHTP] [hereinafter 
BELMONT REPORT].  
80 See Gonzales v. Oregon, 546 U.S. 243, 270 (2006) (citing Medtronic, Inc. v. Lohr, 
518 U.S. 470, 475 (1996) (quoting Metro. Life Ins. Co. v. Massachusetts, 471 U.S. 724, 756 
(1985)). 
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of medical practice committees, for example, to insist that a major 
innovation be incorporated into a formal research project.81 
 
More specifically, Professor Nancy King observes that “specialties such as surgery, 
emergency and trauma medicine, and brain and spinal cord injury and rehabilitation” 
have been “historically exempted from standardized research pathways.”82 Thus, 
even though novel techniques are incorporated in surgery, the surgical realm of 
medical practice is not regulated by the FDA and is minimally regulated by 
individual states (to the extent that medical malpractice laws would apply ex post in 
the case of a harmful surgical procedure).83 As such, novel heart surgeries, for 
example, are part of the practice of medicine and are not submitted to the FDA for 
premarket approval.84 Similarly, even if one looks at the history of organ 
transplantation, while pharmaceutical protocols involved in antirejection measures, 
for example, might involve the action of the FDA, the transplantation techniques 
themselves are not subject to federal regulation.85 Thus, even though surgery 
involves innovative techniques (and the use of pharmaceuticals and medical devices 
before, during, and after surgical procedures), this area of medical practice is not 
subject to the FDA’s jurisdiction.86  
  
                                               
81 BELMONT REPORT, supra note 79, at 5 (emphasis added) (citations omitted). 
82 King, supra note 79, at 575. 
83 See, e.g., Jonathan J. Darrow, Explaining the Absence of Surgical Procedure 
Regulation, 27 CORNELL J.L. & PUB. POL’Y 189, 190 (2017) (“Yet, notwithstanding the 
frequency of surgical procedures and their often critical importance to patient health, no state 
or federal agency either approves the use of new surgical procedures or directly regulates 
existing procedures.”) (citing Robert S. Rhodes, Should Surgery Have an FDA?, AMA J. 
ETHICS (Oct. 2004), https://journalofethics.ama-assn.org/2004/10/pfor2-0410.html)); Anna 
C. Mastroianni, Liability, Regulation and Policy in Surgical Innovation: The Cutting Edge 
of Research and Therapy, 16 HEALTH MATRIX 351, 353–54, 357–59 (2006). 
84 Mastroianni, supra note 83, at 372–98. 
85 See STARZL, supra note 1, at 212, 222, 240 (discussing the process of obtaining 
cyclosporine for use in liver transplantation). But see id. at 295 (“No week goes by without 
a newspaper or television story about overregulation by the FDA that has prevented the 
orderly development of a drug or device, or about under-regulation and release of an unsafe 
product. We were astonished at what we found. Each of the FDA scientists was an expert in 
his or her own right and understood perfectly what we had to report. When we finished, they 
pointed out the gaps in our research (mostly toxicology), what safeguards they thought would 
be necessary if clinical trials ever were to be considered, and how our work so far did or did 
not fulfill FDA requirements. They invited us to return when we had more results to report.”); 
id. (lauding especially the work of Dr. Gregory Burke at the U.S. Food and Drug 
Administration during the time that Dr. Thomas Starzl and others were developing research 
and treatment protocols related to the use of cyclosporine to prevent the rejection of newly 
transplanted human livers).  
86 King, supra note 79, at 575. 
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2.  Drugs 
 
As its name suggests, the FDA has jurisdiction over food and drugs, in addition 
to medical devices, tobacco, and a broader category of tools called “biologics,” but 
not the practice of medicine, which is within the jurisdiction of the states.87 Medical 
innovations are not drugs as they are not “articles,” which is a term used multiple 
times in the definition of “drug.”88 The Federal Food, Drug, and Cosmetic Act 
defines a “drug”:  
 
The term “drug” means (A) articles recognized in the official United 
States Pharmacopœia, official Homœopathic Pharmacopœia of the United 
States, or official National Formulary, or any supplement to any of them; 
and (B) articles intended for use in the diagnosis, cure, mitigation, 
treatment, or prevention of disease in man or other animals; and (C) 
articles (other than food) intended to affect the structure or any function 
of the body of man or other animals . . . .89  
 
The definition of drug was crafted in 1938 and even with amendments, the definition 
has failed to keep pace with the innovations of today.90 For example, “[w]hereas the 
prototypical drug in the late nineteenth century was a natural remedy whose safety 
and effectiveness were established through longstanding practice and traditional 
knowledge, today’s prototypical drug is a synthetic, laboratory-developed substance 
that has been subjected to intensive scientific research and approved by the 
government.”91  
While much of the analysis of innovative medical techniques focuses on the 
idea that they may cure, mitigate, or treat disease, it is important not to neglect the 
term “article” in the definition.92 The word “article” matters because, as the FDA 
                                               
87 21 U.S.C. § 321(g)(1) (2018); 42 U.S.C. § 262(2)(c) (2018); see also Gonzales v. 
Oregon, 546 U.S. 243, 270 (2006) (discussing the state’s historic police power over the 
practice of medicine). 
88 21 U.S.C. § 321(g)(1); see, e.g., Elizabeth C. Price, Does the FDA Have Authority to 
Regulate Cloning?, 11 HARV. J.L. & TECH. 619, 629–34 (1998) (discussing the importance 
of the word “article” in the definition of “drug”). 
89 21 U.S.C. § 321(g)(1). 
90 See, e.g, MICHELLE MEADOWS, PROMOTING SAFE AND EFFECTIVE DRUGS FOR 100 
YEARS, FDA CONSUMER MAG. (2006); see also Javitt & Hudson, supra note 44, at 1219 
(“The [Food Drug & Cosmetic] Act has been amended eighty-eight times since its enactment 
in 1938.”). 
91 Lewis A. Grossman, Food, Drugs, and Droods: A Historical Consideration of 
Definitions and Categories in American Food and Drug Law, 93 CORNELL L. REV. 1091, 
1095–96 (2008). 
92 Id.  
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and many commentators have indicated,93 the FDA does not have jurisdiction over 
the practice of medicine.94 Whereas “drugs” are “articles” or “items,” techniques are 
procedures that are a part of the practice of medicine, and thus not subject to the 
FDA’s jurisdiction.95 Thus, traditional ART techniques such as in vitro fertilization 
or artificial insemination, for example, are not regulated by the FDA because they 
are procedures and not “articles.”96 Extending that analogy, innovative techniques 
such as fecal transplants or stem cell treatments are also procedures as opposed to 
articles. Similarly, while CRISPR-Cas9 will likely involve a delivery method (so as 
to deliver the “product” that will edit the relevant gene(s)), the gene editing itself 
would not be an “article”; as such the entire technique would not fall within the 
FDA’s jurisdiction.97 Instead, as emphasized infra in Part IV, a hybrid method of 
state–federal regulation (to the extent that any federal regulation is involved) would 
likely be required to regulate adequately new innovations in the life sciences.  
 
3.  Biologics 
 
While the definition of “biologic,” another category of product regulated by the 
FDA, is a broad one, innovative new medical techniques studied in this Article likely 
do not fall within that classification either. A “biological product” is defined as  
 
a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood 
component or derivative, allergenic product, protein (except any 
chemically synthesized polypeptide), or analogous product, or 
arsphenamine or derivative of arsphenamine (or any other trivalent 
organic arsenic compound), applicable to the prevention, treatment, or 
cure of a disease or condition of human beings.98  
 
                                               
93 See 21 U.S.C. § 321(g)(1) (providing the definition of “drug” which uses the word 
“articles” four times); see also Price, supra note 88, at 630 (“As an initial matter, it is 
important to note that both of these definitions are limited to ‘articles.’ Thus, if the FDA 
wishes to assert jurisdiction over human cloning under the drug definition of the FDCA, it 
must first identify the requisite ‘article’ to regulate. Although the term ‘article’ is not defined 
in the FDCA itself, the ordinary meaning of the word is ‘a member of a class of things; esp: 
a piece of goods.’”). 
94 See, e.g., Zettler, supra note 61, at 885 (“Conventional wisdom in health law and 
policy holds that states regulate the practice of medicine, while the federal government–
specifically the FDA—regulates drugs.”). 
95 See 21 U.S.C. § 321(g)(1) (providing the definition of “drug” in the Federal Food, 
Drug, and Cosmetic Act). 
96 See supra note 32 and accompanying text; see also Lewis, supra note 13, at 1252–
53 nn. 49–53.  
97 See, e.g., Emily Mullen, Five Ways to Get CRISPR into the Body, MIT TECH. REV. 
(Sept. 22, 2017), https://www.technologyreview.com/s/608898/five-ways-to-get-crispr-
into-the-body/ [https://perma.cc/24CJ-E57P ].  
98 42 U.S.C. § 262(B)(i)(1) (2018). 
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As the definition indicates, “blood,” a “bodily fluid,” merited a specific reference in 
the statute, whereas other parts of the human body are not mentioned.99 Biologics, 
like drugs, have existed for some time in the medical sphere although their nature 
has changed: “Biologics are not new; development of human growth hormone, 
insulin, and red-blood cell stimulating agents occurred decades ago, but the targets 
have increased exponentially with new genetic information and new understanding 
of subcellular cascades and disease processes.”100 So, for example, the human 
growth hormone is not created from an individual’s own hormones, nor is insulin, 
and “red-blood cell stimulating agents” are similarly manufactured hormones that 
are provided in “drug” form.101 Unlike the conventional biologics that often involve 
the use of external material to create what the body lacks, innovative medical 
treatments focus on using the patient’s own tissues or another person’s tissues as a 
treatment.  
 
4.  Regenerative Advanced Therapies 
 
Congress had the opportunity to clarify the definition of “drug” within the 21st 
Century Cures Act, and while the Act accelerated the approval process for certain 
innovations, the statutory classifications created by the Act failed to increase the 
statutory scope of products regulated by the FDA. The 21st Century Cures Act 
identified a new category of products, called “regenerative advanced therapies,” yet 
the addition of this new statutorily recognized category does not resolve the 
jurisdictional challenges that this Article addresses. A “regenerative advanced 
therapy” is a type of “drug.” Thus, while the 21st Century Cures Act has added a 
term to the FDA’s regulatory repertoire, it does not provide an additional definition. 
Regenerative advanced therapies are significant because any drug that is classified 
as a regenerative advanced therapy is eligible for expedited review; yet, it is still a 
“drug.”102 According to the 21st Century Cures Act (as incorporated into the Federal 
Food, Drug, and Cosmetic Act), 
 
                                               
99 See Blood, PUBMED HEALTH, (Sept. 2004) https://www.ncbi.nlm.nih.gov/pubmed 
health/PMHT0022037/ [https://perma.cc/DQ5V-DBEP].  
100 Thomas Morrow & Linda H. Felcone, Defining the Difference: What Makes 
Biologics Unique, BIOTECHNOLOGY HEALTHCARE 24, 24–29 (2004), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564302/ [https://perma.cc/YPZ8-Q9ZG].  
101 See, e.g., Erythropoietin-Stimulating Agents, CLEVELAND CLINIC (Sept. 9, 2014), 
https://my.clevelandclinic.org/health/drugs/14573-erythropoietin-stimulating-agents 
[https://perma.cc/RJC8-PAHB] (“In order to make red blood cells, the body maintains an 
adequate supply of erythropoietin (EPO), a hormone that is produced by the kidney . . . . 
Having more red blood cells raises your hemoglobin levels . . . . Anemia is a disorder that 
occurs when there is not enough hemoglobin in a person’s blood . . . . Anemia can be caused 
by the body’s inability to produce enough EPO. . . .  [In some cases], it may be necessary to 
give the patient recombinant erythropoietin[,] . . . a man-made version of natural 
erythropoietin.”).  
102 21 U.S.C. § 356 (g)(2) (2016). 
2018] HALTED INNOVATION 1095 
 
A drug is eligible for designation as a regenerative advanced therapy 
under this subsection if-- 
(A) the drug is a regenerative medicine therapy (as defined in 
paragraph (8)); 
(B) the drug is intended to treat, modify, reverse, or cure a serious or 
life-threatening disease or condition; and 
(C) preliminary clinical evidence indicates that the drug has the 
potential to address unmet medical needs for such a disease or 
condition.103 
 
Section 356 of the Food, Drug, and Cosmetic Act (as amended by the 21st Century 
Cures Act) explains that  
 
For purposes of this section, the term “regenerative medicine therapy” 
includes cell therapy, therapeutic tissue engineering products, human cell 
and tissue products, and combination products using any such therapies or 
products, except for those regulated solely under section 361 of the Public 
Health Service Act and part 1271 of title 21, Code of Federal 
Regulations.104 
 
Thus, as indicated, “regenerative medicine therapy” is a term whose definition is 
provided for the purposes of Section 356 (referred to as “this section” in the above-
quoted language) of the Federal Food, Drug, and Cosmetic Act, which is entitled 
“Expedited approval of drugs for serious or life-threatening diseases or 
conditions.”105 Yet, the statutory provision did not define the terms used in the 
definition of “regenerative medicine therapy.” Instead, the terms used in the 
definition of “regenerative medicine therapy” remain vaguely defined in FDA 
regulations; furthermore, these unclear definitions are accompanied by similarly 
vague, non-binding guidance documents that attempt to explain what these terms 
mean in the FDA’s regulatory space.106 As such, instead of clarifying what a drug 
is, which is defined in Section 321 of the Federal Food, Drug, and Cosmetic Act, 
legislators made an administrative determination in the 21st Century Cures Act as 
to which “drugs” merit priority review by a federal agency.107  
                                               
103 Id.  
104 21 U.S.C. § 356 (g)(6) (2016). The term “regenerative medicine therapy” is also 
used in Section 506(g) of the 21st Century Cures Act, “Standards for Regenerative Medicine 
and Regenerative Advanced Therapies” (codified at 21 USC § 356(g) (2016)) which 
addresses evidentiary standards for the approval of such therapies, along with Sec. 3034. 
Guidance regarding devices used in the recovery, isolation, or delivery of regenerative 
advanced therapies (codified at 21 USC § 356(g). and Sec. 3035. Report on regenerative 
advanced therapies (codified at 21 USC § 356). 
105 21 U.S.C. § 356.  
106 See, e.g., infra Part II.B.1 (discussing the FDA’s Human Cellular and Tissue-Based 
Products Rule).  
107 Section 321 of the Federal Food, Drug, and Cosmetic Act is codified at 21 U.S.C. § 
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* * * 
 
The statutory language of the Federal Food, Drug, and Cosmetic Act does not 
permit an extensive construction of the terms “drug” or “biologic” so as to 
incorporate the human body. Furthermore, the 21st Century Cures Act does not 
provide additional jurisdictional authority, even though proponents and authors of 
the legislation knew of forthcoming innovative life sciences, with an emphasis on 
the use of autologous stem cells.108 Thus, the FDA’s regulatory perspective is based 
on an unreasonable construction of the statute as the FDA has yet to explain how the 
human body is an article subject to regulation. Second, it is impermissible to 
construe the statute so as to cover genetic modifications and unforeseen inventions. 
The next Section provides background on the ad hoc regulatory structure that the 
FDA has created in order to apply the Federal Food, Drug, and Cosmetic Act to the 
unforeseen inventions of the life sciences. It then explains how the FDA has 
specifically targeted many life-sciences innovations for federal regulation even 
though an agency should not govern in the absence of statutory direction.  
 
B.  FDA Regulations and Guidance Documents 
 
The FDA regulates techniques involving genetic modifications in a 
subterranean manner.109 Subterranean regulation is characterized by (1) a lack of 
jurisdiction; (2) regulation through letters instead of clearly applicable rules; and (3) 
a chilling effect on research.110 This Article has demonstrated that subterranean 
regulation is not limited to ART, but that it indeed extends to a number of 
innovations in the life sciences. Specifically, the FDA references its rule on human 
cells, tissues, and cellular and tissue-based products (Human Cellular and Tissue-
Based Products Rule) in communications that it issues to physicians and researchers 
that aim to hinder the clinical use of innovative medical techniques.111  
  
                                               
321(g)(1) (2018). 
108 See, e.g., 21st Century Cures Act, Beau Biden Cancer Moonshot and NIH Innovation 
Projects, Pub. L. No. 114–255, § 1001(b)(D), available at https://www.congress.gov/bill/ 
114th-congress/house-bill/34/ [https://perma.cc/6AEF-9FCT] (“For the National Institutes 
of Health, in coordination with the Food and Drug Administration, to award grants and 
contracts for clinical research to further the field of regenerative medicine using adult stem 
cells, including autologous stem cells, for which grants and contracts shall be contingent 
upon the recipient making available non-Federal contributions toward the costs of such 
research in an amount not less than $1 for each $1 of Federal funds provided in the award, 
not to exceed a total of $30,000,000, as follows . . . .” (emphasis added)).  
109 See Lewis, supra note 13, at 1272–73. 
110 Id. at 1254–56.  
111 Id. at 1266–71. 
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1.  Human Cellular and Tissue-Based Products Rule  
 
Notice-and-comment rulemaking, has been described as a method to allay the 
negative aspects of regulatory decision-making; however, it is not without fault.112 
The FDA bases its regulation of innovative medical techniques, especially those 
involving genetic modifications, on the agency’s Human Cellular and Tissue-Based 
Products Rule.113 While the regulation was subject to the notice-and-comment 
process, it still suffers from various shortcomings. For example, the regulation itself 
is written unclearly, despite public comments suggesting modification.114  
The FDA’s Human Cellular and Tissue-Based Products Rule uses the term 
“minimally manipulated,”115 which has a counter-intuitive meaning.116 The term 
surfaces not only in the FDA’s communications with researchers that the agency 
sees as operating without its approval but also in at least one federal court decision 
addressing the legality of the actions of physicians and researchers.117 “Minimal 
manipulation” is “processing that does not alter the original relevant characteristics 
of the tissue relating to the tissue’s utility for reconstruction, repair, or 
replacement . . . [or] the relevant biological characteristics of cells or tissues.”118 The 
regulation does not further define the other terms used in the definition of “minimal 
manipulation” such as “original relevant characteristics,” “relevant biological 
characteristics,” or “utility.”119 During the notice-and-comment process (prior to the 
finalization of the rule), various public commenters objected to the use of the term 
“minimal manipulation”; however, the FDA still retained the term.120  
                                               
112 Mark Seidenfeld, Who Decides Who Decides: Federal Regulatory Preemption of 
State Tort Law, 65 N.Y.U. ANN SURV. AM. L. 611, 645 (2010) [hereinafter Seidenfeld, Who 
Decides Who Decides]; see also id. at 649 (“In addition, scholars have reported that in several 
instances, agencies have abused the notice-and-comment process by sneaking preemption 
provisions into the preamble to rules thereby avoiding the notice-and-comment process 
altogether.” (citing Catherine Sharkey, Federalism Accountability: “Agency-Forcing” 
Measures, 58 DUKE L.J. 2125, 2131–34 (2009)).  
113 See Human Cells, Tissues, and Cellular and Tissue-Based Products; Establishment 
Registration and Listing, 66 Fed. Reg. 5447 (Jan. 19, 2001) (codified at 21 C.F.R. pts. 207, 
807, 1271 (2018)), available at https://www.gpo.gov/fdsys/pkg/FR-2001-01-19/pdf/01-
1126.pdf [https://perma.cc/DWB8-QEN5] [hereinafter Human Cells]. 
114 See id. at 5450–62.  
115 Id. at 5457.  
116 Id. (discussing submitted comments which described the term as “vague and open 
to subjective interpretation”).  
117 See discussion infra Part II.B.2.c. (discussing U.S. v. Regenerative Sciences and the 
FDA’s letters to other providers of innovative techniques such as OvaScience and Celltex).  
118 Human Cells, supra note 113, at 5467.  
119 Id.  
120 See id. at 5457 (“We disagree that the term should be eliminated . . . .”); see also 
United States v. Regenerative Scis., LLC, 741 F.3d 1314, 1321–22 (2014); Lewis, supra note 
13, at 1241–44 (discussing the FDA’s issuance of Untitled Letters to providers of 
cytoplasmic transfer). 
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While non-legislative documents have been lauded for providing benefits such 
as flexibility in nascent industries, the FDA uses them to hinder the clinical use of 
innovations in the life sciences. The FDA accomplishes this by subjecting those 
innovations to burdensome regulatory requirements, which has a “chilling effect” 
on their clinical use.121 Other scholars have criticized federal agencies’ overuse of 
guidance documents, with some specifically criticizing the FDA’s overuse of non-
legislative rules, including guidance documents.122 On the other hand, those in favor 
of increased deference to federal agencies often note the specialization of agency 
employees.123 Yet, as noted infra, while the FDA certainly has specialists in 
pharmaceutical regulation—especially in regulating drugs, to the extent that drugs 
are pharmaceuticals like analgesics or antidepressants—the deference to agency 
specialization is more difficult to support when it comes to innovative medical 
techniques.124 Considering the recentness of new techniques that focus on using the 
human body to cure ailments and the FDA’s historical role in regulating 
pharmaceuticals as opposed to the practice of medicine, it is less likely that the 
appropriate area of regulatory specialization rests solely with the FDA.  
  
                                               
121 See, e.g., Lewis, supra note 13, at 1241–44 (discussing the FDA’s issuance of 
Untitled Letters to providers of cytoplasmic transfer which ultimately led to the technique 
becoming unavailable in the United States); see also United States v. Regenerative Scis., 
LLC, 878 F. Supp.2d 248, 252 (D.D.C. 2012), aff’d, 741 F.3d 1314 (D.C. Cir. 2014) (noting 
that the FDA sent a letter to Regenerative Sciences in which it “notified Regenerative that 
the FDA believed that the cell product used in the Regenexx™ Procedure constituted a drug 
under the FFDCA and a biological product under the Public Health Service Act, 42 U.S.C. 
§ 262 (‘PHSA’). Further, the FDA stated that because Regenerative had not obtained the 
necessary approvals for the cell product, its actions in this regard were possibly unlawful.”). 
For more on the Regenerative Sciences litigation, see discussion infra Part II.B.2.c; see also 
Tim Wu, Agency Threats, 60 DUKE L.J. 1841, 1850–54 (2011).  
122 For more on guidance documents in general, see generally Seidenfeld, supra note 
25. For FDA-specific criticisms, see generally Lars Noah, Governance by the Backdoor: 
Administrative Law (Lessness?) at the FDA, 93 NEB. L. REV. 89 (2014). See also Nina A. 
Mendelson, Regulatory Beneficiaries and Informal Agency Policymaking, 92 CORNELL L. 
REV. 397, 408 (2007) (“[B]y issuing a guidance document, an agency can obtain a rule-like 
effect while minimizing political oversight and avoiding the procedural discipline, public 
participation, and judicial accountability required by the APA. The prospect of ‘compliance 
for less’ is almost certainly among the reasons that agencies use guidance documents rather 
than go through the effort of notice-and-comment rulemaking.”). 
123 See, e.g., Seidenfeld, Who Decides Who Decides, supra note 112, at 618. 
124 See, e.g., Centers for Disease Control and Prevention, Therapeutic Drug Use, NAT’L 
CENTER FOR HEALTH STATISTICS, https://www.cdc.gov/nchs/fastats/drug-use-
therapeutic.htm [https://perma.cc/7DVK-V9XE] (last visited June 10, 2018).  
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2.  Non-legislative Rules: The FDA’s Current Method of Regulating Innovative 
Medical Techniques 
 
(a)  Genetic Modifications of the Human Body 
 
With the addition of genetic modifications, ART has moved from being an area 
of state regulation and experimentation to an area of federal regulation, resulting in 
additional regulatory barriers.125 For example, the clinical use of forms of ART that 
involve genetic modifications has been hindered by the exercise of agency power 
through non-legislative rules.126 While ART was originally used to aid couples 
dealing with fertility difficulties, a new form of ART, mitochondrial transfer, has 
received significant attention recently due to its ability to prevent the transmission 
of harmful genetic diseases from parents to their children.127 As noted in Part I, 
clinical trials related to mitochondrial transfer are underway in the United Kingdom, 
while in the United States, the technique has been subjected to burdensome 
regulatory requirements, resulting in a chilling effect on research and clinical use of 
the technique.128 For years, the FDA would send letters to physicians and researchers 
stating that in order for those individuals to continue using innovative techniques 
like mitochondrial transfer and a related technique, cytoplasmic transfer, they would 
have to submit an investigational new drug application as a part of the FDA’s 
extensive (and expensive) drug-approval process.129 As a result, U.S.-based 
physicians have provided the technique abroad, most notably in Mexico, in order to 
avoid the restrictive regime created by the FDA.130 
                                               
125  For an overview of state laws related to assisted reproductive technology, see 
generally CHARLES P. KINDREGAN, JR. & MAUREEN MCBRIEN, ASSISTED REPRODUCTIVE 
TECHNOLOGY: A LAWYER’S GUIDE TO EMERGING LAW AND SCIENCE (2d ed. 2011) 
(chronicling the ongoing legal developments within the field of ART). 
126 See, e.g., Restrictions on Mitochondrial Replacement Techniques, supra note 33. 
127 See, e.g., Doctors given approval for UK's first ‘three-person babies,’ BBC NEWS 
(Feb. 2, 2018), http://www.bbc.com/news/health-42918341 [https://perma.cc/3ECL-
SA7W]; Paula Amato et. al., Three-Parent IVF: Gene Replacement for the Prevention of 
Inherited Mitochondrial Diseases, FERTILITY AND STERILITY (2014), available at 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4005382/pdf/nihms-571742.pdf 
[https://perma.cc/EY9Z-62A4]; Human Cells Used in Therapy, supra note 34.  
128 See, e.g., James Masters, “Three-parent” babies approved in the UK, CNN (Dec. 
15, 2016), http://www.cnn.com/2016/12/15/health/babies-three-people-embryos/index.html 
[https://perma.cc/K3UU-DJVH]. 
129 Id.; see also Jason Millman, Does it really cost $2.6 billion to develop a new drug?, 
WASH. POST (Nov. 18, 2014), https://www.washingtonpost.com/news/wonk/wp/2014/11/18 
/does-it-really-cost-2-6-billion-to-develop-a-new-drug/?utm_term=.45ffc90434b4 
[https://perma.cc/DZE3-Q7XZ]. 
130 Michelle Roberts, First ‘three person baby’ born using new method, BBC (Sept. 27, 
2016), http://www.bbc.com/news/health-37485263 [https://perma.cc/GQX9-9EXN] (noting 
also that the provision of mitochondrial transfer to a Jordanian family in Mexico by U.S. 
based physicians aimed to avoid maternal transmission of Leigh Syndrome: “Leigh 
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AUGMENT—a method that uses a woman’s own genetic material to improve 
her fertility—is another innovative technique that has been the subject of the FDA’s 
subterranean regulation.131 After telling its shareholders for some time that the 
technique would not have to go through the FDA’s extensive regulatory process for 
premarket approval, OvaScience, the creator of AUGMENT, received a letter from 
the FDA informing the company otherwise: If OvaScience wished to continue 
providing AUGMENT in the United States, then it would need to be approved 
through the FDA’s extensive investigational new drug application and approval 
process.132 Now, OvaScience only provides AUGMENT to patients outside the 
United States.133 While it is certainly useful for companies to discover that the FDA 
                                               
syndrome . . . would have proved fatal to any baby conceived. The family had already 
experienced the heartache of four miscarriages as well as the death of two children—one at 
eight months and the other at six years of age.”).  
131 See 21st Century Cures Act, supra note 6 and accompanying text.  
132  See FOIA REQUEST 2016-4882 (on file with author) (The FDA’s letter noted, in 
pertinent part: 
 
Our understanding is that your autologous mitochondrial transfer product, 
AUGMENT, consists of cells isolated from a biopsy of ovarian tissue, which are 
processed to extract mitochondria that are then introduced into other reproductive 
tissues during the IVF process. The removal of mitochondria and introduction into 
other reproductive tissue appears to be more than minimal manipulation. This is 
based on the limited information available; please note that the addition of 
mitochondrial DNA to other reproductive tissue may raise additional regulatory 
concerns.  
 
See also Complaint at 2, Ratner v. OvaScience Inc., 134 F.Supp. 3d 621 (D. Mass. 2013) 
(No. 14-12412) (“Throughout the Class Period, Ova[S]cience represented to the FDA and 
investors that it believed that Augment qualified for designation as a 361 HCT/P, which 
allows human cellular and tissue based products to be tested and marketed without FDA 
licensure. Under FDA guidelines, organisms can only achieve this designation if they are 
‘only minimally manipulated,’ i.e., the process does not alter ‘the relevant biological 
characteristics of the cells or tissue.’ . . . Ultimately, the FDA rejected OvaScience’s faulty 
designation. On September 10, 2013, the Company disclosed that it was suspending 
enrollment of AUGMENT in the U.S. after receiving an ‘untitled’ letter from the FDA 
‘questioning the status of AUGMENT as a 361 HCT/P and advising the Company to file an 
Investigational New Drug (IND) application.’”). 
133 Id.; see also OVASCIENCE, INC, FORM 10-K 14 (2016), http://ir.ovascience.com/ 
static-files/0b856624-270a-4dc6-be45-b337e3317092 [https://perma.cc/6DCG-QF84] 
(“The United States does not have a fertility regulatory body separate and apart from the 
FDA. In September 2013, we received an ‘untitled’ letter from the FDA advising us to file 
an IND application for the AUGMENT treatment. Following the receipt of the FDA letter, 
we chose to suspend the availability of the AUGMENT treatment in the United States. We 
plan to meet with the FDA in the first half of 2017, as part of our ongoing exploration of 
potential entry into the U.S. market.”); Pipeline and Treatments, OVASCIENCE, 
http://www.ovascience.com/treatments/ [https://perma.cc/YCL5-TFRE] (last visited June 
10, 2018).  
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has “flagged” their techniques for potential enforcement action, it does not resolve 
the crucial issue of whether the FDA should target them for enforcement action in 
the first place, based on its statutory mandate.  
The FDA took a similar approach to cloning in 1998, which does not receive 
in-depth treatment in this Article because human reproductive cloning has not been 
identified as a treatment for any ailments.134 The FDA took this approach even 
though members of Congress had tried (and failed) multiple times to pass legislation 
that would specifically prohibit human reproductive cloning in the United States, 
suggesting that at least some of those individuals responsible for defining the FDA’s 
jurisdiction were concerned that the current regime was insufficient.135 
 
(b)  Fecal Microbiota Transplants 
 
Fecal microbiota transplants should not be subject to FDA regulation as they 
are not “drugs” or “biologics.” Further, the FDA has not explained what about these 
techniques renders them “drugs” or “biologics.” Nonetheless, the FDA has asserted 
that it has jurisdiction over these procedures through guidance documents, another 
way of regulating in a confusing manner.136 Guidance documents represent a 
confusing way of regulating because they are not binding upon the agencies that 
issue them, and—as illustrated by changes in the FDA’s guidance documents related 
                                               
134 Stuart L. Nightingale, Letter About Human Cloning, U.S. FOOD & DRUG ADMIN. 
(Oct. 26, 1998), https://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinical 
Trials/ucm150508.htm [https://perma.cc/3NQJ-UQAM] (“The purpose of this letter is to 
confirm to institutional review boards (IRBs) that the Food and Drug Administration (FDA) 
has jurisdiction over clinical research using cloning technology to create a human being, and 
to inform IRBs of the FDA regulatory process that is required before any investigator can 
proceed with such a clinical investigation.”).  
135 Richard A. Merrill & Bryan J. Rose, FDA Regulation of Human Cloning: 
Usurpation or Statesmanship?, 15 HARV. J.L. & TECH. 85, 98–99 (2001); See also The Great 
Cloning Debate, ECONOMIST, May 9, 2002, https://www.economist.com/node/1125284 
[https://perma.cc/BH5H-BTGB].  
136 See FDA, ENFORCEMENT POLICY REGARDING INVESTIGATIONAL NEW DRUG 
REQUIREMENTS FOR USE OF FECAL MICROBIOTA FOR TRANSPLANTATION TO TREAT 
CLOSTRIDIUM DIFFICILE INFECTION NOT RESPONSIVE TO STANDARD THERAPIES: DRAFT 
GUIDANCE FOR INDUSTRY, 1 (2016), available at https://www.fda.gov/downloads/biologics 
bloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm488223.
pdf [https://perma.cc/CSC6-FJ8N] [hereinafter 2016 GUIDANCE]; see also FDA, GUIDANCE 
FOR INDUSTRY: ENFORCEMENT POLICY REGARDING INVESTIGATIONAL NEW DRUG 
REQUIREMENTS FOR USE OF FECAL MICROBIOTA FOR TRANSPLANTATION TO TREAT 
CLOSTRIDIUM DIFFICILE INFECTION NOT RESPONSIVE TO STANDARD THERAPIES 1 (2013), 
available at https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplian 
ceRegulatoryInformation/Guidances/Vaccines/UCM361393.pdf (explaining prior 
enforcement guidance on the use of fecal microbiota transplants in the United States) 
[https://perma.cc/PK95-6T9A] [hereinafter 2013 GUIDANCE]. 
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to fecal microbiota transplants—they can be withdrawn and replaced far more easily 
than agency regulations.137  
The FDA’s interpretation of the law is that an investigational new drug 
application is necessary in order to carry out a fecal microbiota transplant in the 
United States.138 Initially, just as with the use of forms of ART that involve genetic 
modifications, the FDA stated that physicians performing fecal transplants must 
submit an investigational new drug application similar to that which pharmaceutical 
companies must submit to have a new drug approved.139 Ultimately, the FDA 
changed its policy for fecal transplants involving known, but not unknown, 
donors.140 Specifically, the agency has stated that it “intend[s] to exercise 
enforcement discretion under limited conditions, regarding the investigational new 
drug (IND) requirements for the use of fecal microbiota for transplantation (FMT) 
to treat Clostridium difficile (C. difficile) infection not responding to standard 
therapies.”141 In other words, the FDA will not pursue legal action against physicians 
who comply with the provisions outlined in the guidance document; however, there 
is no guarantee of continued enforcement discretion as the agency’s statement comes 
through a nonbinding document.142  
The FDA announced this policy change through a guidance document which 
includes a prominent disclaimer on the first page, stating:  
 
This draft guidance, when finalized, will represent the current 
thinking of the Food and Drug Administration (FDA or Agency) on this 
topic. It does not establish any rights for any person and is not binding on 
FDA or the public. You can use an alternative approach if it satisfies the 
requirements of the applicable statutes and regulations. To discuss an 
alternative approach, contact the FDA staff responsible for this guidance 
as listed on the title page.143  
 
As indicated by the FDA’s language, guidance documents are not legally 
enforceable; the agency could implement a different policy in enforcement actions, 
and those acting in accordance with the guidance document would have no legal 
protection by “relying” on the agency’s expressed position. Additionally, stool 
banks are not beneficiaries of the FDA’s intent to exercise enforcement discretion.144 
By targeting stool banks, the guidance document, to the extent that it is binding (or 
                                               
137 See 2013 GUIDANCE, supra note 136 (“FDA’s guidance documents, including this 
guidance, do not establish legally enforceable responsibilities. Instead, guidances describe 
the FDA’s current thinking on a topic and should be viewed only as recommendations, unless 
specific regulatory or statutory requirements are cited.”).  
138 Id.  
139 Id.  
140 2016 GUIDANCE, supra note 136, at 3. 
141 Id. at 1. 
142 Id.   
143 Id.  
144 Id. at 3. 
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influences decision-making in the way that binding guidance would), minimizes the 
number of available donors.145 
As a result, the limited options available to physicians and patients are (1) to 
submit an investigational new drug application, which comes with extremely high 
costs (both in time and in research funding) or (2) to follow a guidance document 
that clearly states it is not final and that limits the availability of donors to aid 
patients, as based on an FDA assertion of “jurisdiction.”146 The FDA has exerted 
authority over another aspect of the practice of medicine—fecal transplants—to the 
chagrin of many patients who travel to other States to find sympathetic physicians 
after their primary physicians refuse to perform the procedure or watch YouTube 
videos to prepare for their own at-home attempts of procedures that their physicians 
will not perform.147 Similarly, the websites of major academic hospitals offering 
fecal transplants indicate that physicians understand that they must proceed relying 
upon the FDA’s enforcement discretion, which is unpredictable.148 
 
(c)  Stem Cell Treatments 
 
The promise of stem cell research is being stymied by FDA regulation. In spite 
of an FDA employee-authored article in the New England Journal of Medicine 
asserting at the outset that the agency shared the “current excitement over the 
                                               
145 See id. at 1 (“The consent should include, at a minimum, a statement that the use of 
FMT products to treat C. difficile is investigational and a discussion of its reasonably 
foreseeable risks; 2) the FMT product is not obtained from a stool bank; and 3) the stool 
donor and stool are qualified by screening and testing performed under the direction of the 
licensed health care provider for the purpose of providing the FMT product for treatment of 
the patient.”).  
146 But see id. at 3 (stating that waivers may be available for investigational new drug 
application sponsors who are “within” or “affiliated with a stool bank”). Nonetheless, the 
guidance is still non-binding and there is no guarantee that a waiver will be granted. See FDA 
Struggles, supra note 46 (“Duff says the unresolved status of FDA’s oversight discourages 
more doctors from offering the treatment. ‘There are so many doctors who are suspicious 
that the FDA could change their mind at any given moment and decide to not exercise 
discretion,’ Duff says.”); Maryn McKenna, Fecal Transplants: They Work, the Regulations 
Don’t, WIRED (Dec. 9, 2011 6:20 AM) https://www.wired.com/2011/12/fecal-transplants-
work/ [https://perma.cc/CT3A-5DRD] (noting that an investigational new drug application 
is necessary for NIH Funding of fecal transplantation); Millman, supra note 129. 
147 See, e.g., Doctors Using Fecal Transplants, supra note 46; see also FDA Struggles, 
supra note 46; Mary Brophy Marcus, Fecal transplants need better regulation, experts say, 
CBS NEWS (Oct. 23, 2015 6:00 AM) https://www.cbsnews.com/news/fecal-transplants-
need-better-regulation-experts-say/ [https://perma.cc/8FBT-AY8E]. 
148 See, e.g., MAYO CLINIC, supra note 27 (“Maria I. Vazquez Roque, M.D., a 
gastroenterologist at Mayo Clinic’s campus in Jacksonville, Florida, observes that the Food 
and Drug Administration (FDA) initially proposed requiring investigational new drug (IND) 
status for FMT procedures. That stance would have denied access to the procedure for many, 
if not most, patients and was later changed. For the time being, the FDA exercises enforced 
discretion.”) [https://perma.cc/Q6VG-TW89]. 
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potential for stem cell therapy to improve patient outcomes or even cure diseases,” 
the agency’s actions are somewhat contrary to that message.149 Instead, the agency’s 
position, as indicated by the content of its publication in the New England Journal 
of Medicine, is that there is a “lack of evidence” as it relates to the “effectiveness of 
stem-cell treatments.”150 The use of stem cells as an alternative to open heart surgery 
(and, in at least one case, after open heart surgery had failed) has also been hindered 
due to the FDA’s action.151 Thus, the use of autologous stem cells represents another 
area in which clinical innovation—which has generally occurred without federal 
involvement—is stymied through the current regulatory apparatus. 152  
Consequently, those physicians who want to use these innovative procedures 
in their practice must await research trials related to the use of stem cells in the 
treatment of cardiac problems such as cardiomyopathy (a disease that can cause 
heart failure), even if such treatments would be the only option to save a patient.153 
In the meantime, clinical trials have been taking place abroad and at certain U.S. 
research hospitals.154  
                                               
149 Peter W. Marks, Cella M. Witten & Robert M. Califf, Clarifying Stem-Cell 
Therapy’s Benefits and Risks, 376 N. ENGL. J. MED. 1007, 1007 (2017) (the author affiliation 
note at the end of the article indicates that the article is “[f]rom the Food and Drug 
Administration, Silver Spring, MD”). FDA documents confirm the employment of the 
authors, with Robert Califf (the third listed author) having served as the agency’s 
Commissioner from February 2016 until January 2017. See Biography of Robert M. Califf, 
M.D., U.S. FOOD & DRUG ADMIN. (Jan. 26, 2017) https://www.fda.gov/AboutFDA/History/ 
FOrgsHistory/Leaders/ucm537751.htm [https://perma.cc/9PVX-7UTT]; Meet Peter Marks, 
M.D., Ph.D., Director, Center for Biologics Evaluation and Research, U.S. FOOD & DRUG 
ADMIN. (Jan. 15, 2016) https://www.fda.gov/AboutFDA/CentersOffices/ucm481936.htm 
[https://perma.cc/X2AN-KB7V]; CBER: Key Staff Directory, U.S. FOOD & DRUG ADMIN. 
(May 14, 2018) https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProducts 
andTobacco/CBER/ucm123224.htm [https://perma.cc/5QYL-PBQN]. 
150 Marks, Witten & Califf, supra note 149, at 1008. 
151 See Epstein, supra note 11, at 1–2. 
152 See Wash. Legal Found. v. Kessler, 800 F. Supp. 26, 35–36 (D.D.C. 1995) 
(“Although the FDA characterizes the ‘regulatory letters’ and other statements of FDA 
officials as merely ‘advisory,’ the court must not be blind to the practical effects of these 
letters and other statements.”). 
153 See Kristen R. W. Matthews & Ana S. Iltis, Unproven Stem Cell-Based Interventions 
and Achieving a Compromise Policy Among the Multiple Stakeholders, 16 BMC MEDICAL 
ETHICS, no. 69, 2015, at 1, 1–2; Shigeru Miyagawa, Phase I Clinical Trial of Autologous 
Stem Cell—Sheet Transplantation Therapy for Treating Cardiomyopathy, 6 J. AM. HEART 
ASSOC., Apr. 2017, at 1 [https://perma.cc/T4G7-CLCZ] (this study concluding that stem-cell 
treatment is feasible for treating cardiomyopathy); News Release, JOHNS HOPKINS MED., 
Stem Cell Therapy Safely Repairs Damaged Heart Muscle in Chronic Heart Failure Patients, 
Study Shows (Nov. 6, 2012), http://www.hopkinsmedicine.org/news/media/releases/stem_ 
cell_therapy_safely_repairs_damaged_heart_muscle_in_chronic_heart_failure_patients_stu
dy_shows [https://perma.cc/LQC6-TQPX]; see also Cardiomyopathy, MAYO CLINIC, 
https://www.mayoclinic.org/diseases-conditions/cardiomyopathy/symptoms-causes/syc-
20370709 [https://perma.cc/BBQ8-VTQE] (last visited June 10, 2018). 
154 Miyagawa, supra note 153, at 2 (referring to clinical research taking place in Japan); 
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The use of autologous stem cells in the treatment of patients has been hindered 
by the FDA. In 2013, based on a combination of the Federal Food, Drug & Cosmetic 
Act, Public Health Service Act, and deference to agency interpretations of FDA 
regulations related to human cells and tissue, the U.S. Court of Appeals for the D.C. 
Circuit upheld a district court ruling that combining a patient’s own stem cells with 
an antibiotic must be approved by the FDA.155 Gonzales v. Raich, the 
aforementioned 2005 Supreme Court decision holding that the Controlled 
Substances Act did not exceed Congress’s power under the Commerce Clause, was 
also cited to in the federal case that held that the FDA’s prohibition of autologous 
stem cells as an alternative to orthopedic surgery was not outside of the agency’s 
jurisdiction.156  
U.S. v. Regenerative Sciences, Inc. addressed whether autologous stem cell uses 
were subject to FDA regulation.157 The stem cell treatment at issue, the “Cultured 
Regenexx Procedure,” was “jointly developed” by two physicians as a “‘treatment 
[for] orthopedic injuries and arthritis’ and for ‘musculoskeletal and spinal 
injury.’”158 While the physician recipients of untitled letters from the FDA often 
cease their offerings of “controversial” techniques after receiving the letters, the 
story of the FDA’s ban of these Colorado physicians’ practice of using of autologous 
stem cells is comparatively complete.159 This is because, instead of ceasing their 
practice after receiving the notice from the FDA as physicians tend to do (or moving 
their practice abroad), Regenerative Sciences litigated the case.160  
                                               
JOHNS HOPKINS MED., supra note 153 (referring to a “preliminary study by researchers at 
the Johns Hopkins University School of Medicine and the University of Miami Miller School 
of Medicine.”); Matthews & Iltis, supra note 153, at 2 (“While some patients find clinics 
within the US offering unproven [stem cell-based interventions], many travel abroad, often 
to countries with less developed medical infrastructures and regulatory oversight, a concept 
or practice often referred to as [stem cell] tourism.”). 
155 United States v. Regenerative Scis., LLC, 741 F.3d 1314, 1317, 1326 (D.C. Cir. 
2014). 
156 Id. at 1320 (citing to Gonzales v. Raich, 545 U.S. 1, 17 (2005)).  
157 Id. at 1318. 
158 Id. at 1317–18 (“The Procedure begins with the extraction of a sample of a patient’s 
bone marrow or synovial fluid. From that sample, Regenerative Sciences isolates 
mesenchymal stem cells (MSCs), which are capable of differentiating into bone and cartilage 
cells. The MSCs are then placed in a solution to culture them—that is, to cause them to divide 
and proliferate. Other substances are sometimes added to the solution that affect the MSCs’ 
differentiation. The culturing process determines the growth and biological characteristics of 
the resulting cell population. When the MSCs are sufficiently numerous for re-injection, they 
are combined with doxycycline, an antibiotic obtained in interstate commerce and used to 
prevent bacterial contamination of the MSCs. The resulting mixture (the Mixture) is injected 
into the patient from whom the stem cell sample was initially taken, at the site of the damaged 
tissue.”).  
159 See, e.g., Lewis, supra note 13, at 1241–42 (noting the impact of FDA “Untitled 
Letters” on physicians practicing in the field of assisted reproductive technology involving 
genetic modifications in the United States).  
160 Regenerative Scis., 741 F.3d at 1314. 
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In Regenerative Sciences, the appellants’ federalism-based argument, which 
focused on the “practice of medicine,” failed.161 The D.C. Circuit held that the FDA 
was targeting the mixture of stem cells and an antibiotic and not a procedure and 
also that the argument related to what constituted the practice of medicine in 
Colorado failed.162 As the Regenexx litigation focused on a federal agency and an 
alleged infraction involving interstate commerce, the Administrative Procedure Act 
and associated federal regulations were critical to the court’s analysis.163 More 
specifically, the aforementioned “minimal manipulation,” an imprecise term that the 
FDA continues to use to regulate human tissue (from ART to stem cell research) 
was central to the court’s analysis.164 The court cited to the FDA’s regulations and 
definition of “minimal manipulation,” which is “processing that does not alter the 
relevant biological characteristics.”165 As noted by members of the public during the 
comment period, the term is “vague”; there is no definition of “relevant biological 
characteristics.”166 However, the appellants did not contest the meaning of “minimal 
manipulation.”167 The court stated that it did not defer to the FDA’s statement in the 
Preamble of the Part 1271 regulations; however, it at least agreed with that 
interpretation.168 Ultimately, the physicians were unsuccessful in the Regenexx 
litigation;169 however, the litigation provides insight into the difficulties of 
regulating novel medical techniques and the perils of deference to the FDA.  
Despite the physicians’ failure in Regenerative Sciences, it is still possible for 
future litigation to succeed. First, the physicians did not contest the applicability of 
the plain language of the statutes, thus leaving room for a successful argument based 
on this issue.170 Second, the physicians did not challenge the definition and use of 
the term “minimal manipulation.” While one could argue that the relevant biological 
characteristics were not altered and that the Regenexx procedure simply increased 
the number of stem cells in a way that did not result in FDA jurisdiction, this issue 
was never raised. Similarly, on the subject of the mesenchymal stem cells isolated 
in the Regenexx procedure, there were some claims that the physicians did not 
                                               
161 Id. at 1319.  
162 Id.  
163 Id. at 1321–24. 
164 Id.  
165 Id. at 1321 (citing 21 C.F.R. §1271.3(f)(2) (2016)).  
166 See Human Cells, supra note 113 (“Eight comments asserted that ‘minimal 
manipulation’ is vague and open to subjective interpretation, and should be eliminated. Two 
comments asserted that it is difficult to draw a meaningful distinction between tissues that 
are minimally manipulated and those that are more than minimally manipulated. One of these 
comments suggested that instead of the minimal manipulation criterion, FDA should propose 
that tissue products labeled or promoted for tissue replacement, reconstruction, or restoration 
of function be regulated as tissue. Another comment requested the development of guidance 
and noted that, in light of future technological advances, a broader definition of minimal 
manipulation may be more appropriate.”).  
167 Regenerative Scis., 741 F.3d at 1322. 
168 Id.  
169 Id. at 1325–26.  
170 Id. at 1319. 
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respond to during the litigation.171 Furthermore, there were manufacturing violations 
in the Regenerative Sciences case that other physician–defendants’ practices may 
not have.172  
Regenexx is not the only stem cell treatment that the FDA has targeted. In 
addition to targeting Regenexx, the FDA has targeted other treatments involving the 
use of autologous stem cells; similarly, those uses of autologous stem cells have 
been deterred through the receipt of an FDA-issued untitled letter.173 For example, 
one of the amicus briefs in Regenerative Sciences was filed by an attorney for 
William Timothy Moore.174 Mr. Moore “received three intravenous infusions (once 
a month for three months) of 200,000,000 of his [own] stem cells” to alleviate 
symptoms related to Parkinson’s disease using a procedure provided by a company 
called Celltex.175 However, as he was preparing to undergo another treatment 
involving the Celltex protocol, Mr. Moore discovered that the FDA had sent a 
warning letter to Celltex, and the company “stopped replicating any cells and would 
not begin again until matters were resolved with the FDA.”176 After being targeted 
by the agency for an inspection (and receiving a warning letter), Celltex has since 
commenced servicing its patients in Mexico.177  
Yet, the federal regulation of stem cell treatments has not automatically resulted 
in harm to patients. For example, the treatments cited to in the New England Journal 
of Medicine article by FDA employees certainly harmed the patients who received 
                                               
171 Id. at 1322; see also Stem Cell Information, NAT’L INSTS. OF HEALTH, (2016) 
https://stemcells.nih.gov/glossary.htm#mesenchymal [https://perma.cc/YRW3-SZKM] 
(“Mesenchymal stem cells - A term that is currently used to define non-blood adult stem 
cells from a variety of tissues, although it is not clear that mesenchymal stem cells from 
different tissues are the same.”). 
172 Regenerative Scis., 741 F.3d at 1325 (The court mentioned the violations and 
concluded that “[t]he fact that the FDA found violations on two separate occasions and that 
appellants refused to take corrective action even after multiple FDA notices suggests a 
pattern of deliberate, even flagrant violations.”).  
173 See, e.g., Letter from Mary A. Malarkey, Director, Office of Compliance and 
Biologics Quality, Center for Biologics Evaluation and Research, To David G. Eller, Chief 
Executive Officer & President, CellTex Therapeutics (Sep. 24, 2012), available at 
https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2012/ucm323853.htm 
[https://perma.cc/KQM9-58CM]. 
174 Brief for Tim Moore as Amicus Curiae Supporting Appellants, Regenerative Scis., 
et al v. United States, No. 12-5254, 2012 WL 6604723 (D.C. Cir. Dec. 17, 2012). 
175 Id. at *viii-ix. 
176 Id. at *ix. 
177 See David Cyranoski, Controversial Stem-Cell Company Moves Treatment Out of 
the United States, NATURE.COM: NEWS (Jan. 30, 2013) 
https://www.nature.com/news/controversial-stem-cell-company-moves-treatment-out-of-
the-united-states-1.12332 [https://perma.cc/6GYA-RQAT]; see also David Cyranoski, 
Texas Stem-Cell Provider Under FDA Gun, NATURE.COM: NEWS BLOG (Oct. 18, 2012) 
http://blogs.nature.com/news/2012/10/texas-stem-cell-provider-under-fda-gun.html 
[https://perma.cc/2K9Q-2N7W]. 
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them.178 Similarly, the FDA’s actions in shutting down harmful stem cell treatment 
providers have been called “spectacular” and “the right thing to do” by individuals 
such as George Daley, the Dean of Harvard Medical School, who is recognized as a 
“leading stem cell researcher.”179 While the full protocols involved in the treatments 
targeted by the FDA (with the support of the U.S. Marshals) were not provided, in 
at least one of these aforementioned enforcement actions, at least one of those 
targeted stem cell “treatments” involved the injection of a live vaccine—intended 
for individuals “at high risk for smallpox”—into patients “intravenously and directly 
into [their] tumors.”180 These techniques differ from the techniques involving the 
combination of an antibiotic with a patient’s own stem cells (as occurs with 
Regenexx). Furthermore, shifting all or part of the regulation of innovative 
techniques from the federal government to the States does not mean that all 
enforcement activity will cease. For example, the Federal Trade Commission 
pursues enforcement action against providers who falsely advertise the safety or 
efficacy of medical products and techniques, including fertility treatments.181 
Additionally, state law creates enforcement mechanisms that can be used against 
those who falsely advertise the efficacy or safety of products or services.182  
  
                                               
178 See Marks, Witten & Califf, supra note 149, at 1008. 
179 See Rob Stein, FDA Cracks Down on Stem-Cell Clinics Selling Unapproved 
Treatments, NPR (Aug. 28, 2017, 2:31 PM) http://www.npr.org/sections/health-
shots/2017/08/28/546719842/fda-cracks-down-on-stem-cell-clinics-selling-unapproved-
treatments [https://perma.cc/8A3W-8W97]; see also New Dean for Faculty of Medicine, 
HARVARD GAZETTE (Aug. 9, 2016) https://news.harvard.edu/gazette/story/2016/08/new-
dean-for-faculty-of-medicine/ [https://perma.cc/B5FV-RLRW]. 
180 Stein, supra note 179; see also FDA Acts to Remove Unproven, Potentially Harmful 
Treatment Used in ‘Stem Cell’ Centers Targeting Vulnerable Patients, U.S. Food & Drug 
Admin. (Aug. 28, 2017) https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements 
/ucm573427.htm [https://perma.cc/R96V-NPET] (“On behalf of the FDA, on Friday, Aug. 
25, 2017 the U.S. Marshals Service seized five vials of Vaccinia Virus Vaccine (Live) – a 
vaccine that is reserved only for people at high risk for smallpox, such as some members of 
the military. Each of the vials originally contained 100 doses of the vaccine, and although 
one vial was partially used, four of the vials were intact. 
As the vaccine is not commercially available, the FDA has serious concerns about how 
StemImmune obtained the product for use as part of an unapproved and potentially 
dangerous treatment. The FDA is actively investigating the circumstances by which 
StemImmune came to possess the vaccine.”). 
181 See, e.g., Sarah Duranske, This Article Makes You Smarter! (Or, Regulating Health 
and Wellness Claims), 43 AM. J.L. & MED. 7, 34, 40–41 (2017); see also NAOMI CAHN, TEST 
TUBE FAMILIES: WHY THE FERTILITY MARKET NEEDS LEGAL REGULATION 193 (2009) (“The 
Federal Trade Commission, which is the federal agency responsible for consumer protection 
and the prevention of anticompetitive practices, has brought complaints against fertility 
clinics for misrepresenting their success rates.”). 
182 See, e.g., Duranske, supra note 181.  
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* * * 
 
This Part has provided the background on how administrative agencies, with an 
emphasis on the FDA, regulate health care and how the line between medical 
practice—an area historically regulated by States—and drugs and devices—an area 
historically regulated by the FDA—has become blurred. This blurring, combined 
with the FDA’s assertion of power outside its jurisdiction, has often operated to the 
detriment of state jurisdiction and patient care.183 There are several statutory 
definitions that could apply to the regulation of the life sciences. The problem, 
however, is that the characteristics of these innovative medical techniques cause 
these techniques to not fit squarely within one category of statutorily defined product 
regulated by the FDA. Furthermore, an integral piece of life sciences jurisdiction 
includes state authority over the regulation of medicine, with an emphasis on clinical 
innovation.  
When it regulates in areas of medical innovation, the federal government is 
infringing in an area in which there is a federal regulatory gap. As a matter of 
practice, instead of the default rule for addressing the regulatory gap being state 
regulation or a cooperative regulatory effort between the federal government and 
States, the federal government encumbers state regulation. And insofar as there has 
been regulation by the state that fails to prevent innovation in these areas, the federal 
government is directly stepping on state power.  
This Part has examined the jurisdictional difficulties of regulating the life 
sciences in general, along with the federal government’s approach to regulating the 
life sciences. Some scholars and policymakers have argued in favor of increased 
federal oversight of medicine, pharmaceuticals, and the health sciences, whereas this 
Article takes the opposite view.184 Instead, after examining the doctrines and 
statutory provisions that could apply to the life sciences, this Article has concluded 
that emergent areas of innovation do not fall within the ambit of federal jurisdiction 
and, alternatively, if they do, the regulatory structure needs significant 
improvements as it was structured to address historical “tools” used in the practice 
of medicine such as pharmaceuticals and medical devices. Furthermore, those 
regulatory improvements are necessary for two significant reasons. First, the current 
regulatory apparatus is minimizing the availability of medical innovations to patients 
in the United States. Second, States own a critical piece of the jurisdictional puzzle 
such that the only method of accurately and adequately regulating the life sciences 
must include the States. The next Part looks at the implications of the current 
regulatory regime, which include jurisdictional overstepping and a risk-averse 
regulatory approach that can be remedied only by a more cooperative regulatory 
apparatus.  
                                               
183 But see supra notes 178–181 and accompanying text (discussing the FDA’s targeting 
of harmful stem cell treatments).   
184 See, e.g., Mary Agnes Cary, Feds v. states: Who should run health market?, NBC 
NEWS (Jan. 15, 2010), http://www.nbcnews.com/id/34868472/ns/health-health_care/t/feds-
vs-states-who-should-run-health-market/#.WS9LdmjyvIU [https://perma.cc/528D-NGXT]. 
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III.  FUTURE IMPLICATIONS: JURISDICTIONAL GAPS AND NASCENT INDUSTRIES 
 
This Section examines the future implications of the continued federal 
regulation of the life sciences before noting that States should play a larger role in 
the regulation of the life sciences. Subsections A and B of this Section explore some 
implications of the current federal regime. Subsection C then asserts that States 
should exert a larger role in the regulation of the life sciences just as they have 
exerted with the legalization of marijuana, which has occurred in the face of federal 
regulation of controlled substances. As explored in Part IV, the federal government 
is not the only actor that should exert jurisdiction over the life sciences.  
 
A.  A Lack of Regulatory Capture  
 
Innovative medical techniques raise different regulatory concerns than 
pharmaceuticals do in the context of FDA regulation. For example, while regulatory 
capture is a concern when analyzing the FDA regulation of pharmaceuticals, it seems 
that the opposite is occurring in the life sciences, where physicians are increasingly 
unable to use innovative medical techniques. 185 Instead, physicians and researchers 
make progress only to be told that the “investigational new drug” requirements 
(which are specifically referred to in the Common Rule) also apply to clinical 
innovations.186 The creation of medical innovations by physicians and university 
researchers as opposed to pharmaceutical companies likely contributes to reduced 
regulatory capture.  This is because physicians and academic medical centers have 
less contact with the agency, and less lobbying power than pharmaceutical 
companies.  In turn, the comparatively lower number of interactions between 
physicians and university researchers and the FDA likely reduces their ability to 
sway the decisions of agency employees (although physicians and university 
employees have certainly created pharmaceuticals and medical devices that are 
subject to the FDA’s jurisdiction).187 Additionally, the number of individuals 
involved in creating innovative medical techniques possibly generates a 
coordination problem amongst the various groups who might seek to “capture” an 
administrative agency.188  
                                               
185 See Bagley & Revesz, supra note 28, at 1289. 
186 See supra Part II.A.1 (discussing mitochondrial transfer and assisted reproductive 
technology). 
187 But see Catherine Ho, Universities opening D.C. offices, hiring in-house lobbyists 
to raise government relations profile, WASH. POST (May 27, 2012), 
https://www.washingtonpost.com/business/capitalbusiness/universities-opening-dc-offices-
hiring-in-house-lobbyists-to-raise-government-relations-profile/2012/05/25/gJQAf7Q3uU_ 
story.html?utm_term=.899736eea633 [https://perma.cc/52L8-LYE3]; see also supra Part 
II.B.2.b (discussing academic medical centers’ opposition to the FDA’s original method of 
regulating fecal microbiota transplantation and subsequent changes to that regulatory plan).  
188 See, e.g., Brenda Reddix-Smalls, Assessing the Market for Human Reproductive 
Tissue Alienability: Why Can We Sell Our Eggs But Not Our Livers?, 10 VAND. J. ENT. & 
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B.  Dual Designations: Biologics and Drugs 
 
While medical practice and the tools used to practice medicine were once 
separate concepts, today’s medical innovations are blurring the line between medical 
practice and medical devices and drugs, in addition to the difference between 
categories of products that the FDA has jurisdiction over under its enabling statutes. 
For example, the FDA designated the aforementioned Regenexx as “both a drug and 
a biological product.”189 The agency has done the same for a number of new products 
as the character of the products regulated by the agency (whether with or without 
jurisdiction) become more complex.190 The recurring term “minimal manipulation” 
is also relevant in this determination as it is one criterion that the agency uses “to 
distinguish between ‘section 361 HCT/Ps [Human Cellular and Tissue-Based 
Products]’ and HCT/Ps regulated as drugs, devices, and/or biological products.”191 
According to a former Chief Counsel for the Agency, “[t]he decision as to which 
Bureau within the FDA handles these products is entirely an administrative matter 
that raises no legal issue”; yet just as the FDA fails to explain how innovative 
products fit within singular categories such as “drug” or “biologic,” the FDA fails 
to explain what about innovative medical techniques leads to such a designation.192  
                                               
TECH. L. 643, 681–82 (2008) (“Administrative agencies may be subject to ‘capture’ by the 
very forces they are designed to regulate. The dominant market forces in assisted 
reproductive technology include the fertility clinics, the physicians, the pharmaceutical 
companies, the suppliers, the representative organizations, the embryo laboratories, the 
gamete middlemen and brokers, and the infertile consumer.”). Similarly, dominant market 
forces in regenerative stem cell treatments could include physicians, pharmaceutical 
companies (to the extent that antibiotics for example were used in the treatments), 
“representative organizations” such as patient advocacy groups, medical suppliers, patients 
themselves, and the facilities at which these treatments would occur. In the case of fecal 
microbiota transplants, one might expect the same composition of dominant market forces 
with the possible removal of pharmaceutical companies and the addition of stool banks. 
189 United States v. Regenerative Scis., LLC, 741 F.3d 1314, 1318 (D.C. Cir. 2014) 
(referring to an August 2010 FDA filing for a permanent injunction against Regenerative 
Sciences, LLC and associated physicians).  
190 See infra notes 194 and 195 and accompanying text; see also About Combination 
Products, U.S. FOOD & DRUG ADMIN. (Mar. 19, 2018), https://www.fda.gov/Combination 
Products/AboutCombinationProducts/default.htm [https://perma.cc/3GEV-AVE4].  
191 See, e.g., PETER BARTON HUTT ET AL., FOOD AND DRUG LAW: CASES AND 
MATERIALS 1172 (4th ed. 2014) (excerpting Richard A. Merrill, Human Tissues and 
Reproductive Cloning: New Technologies Challenge FDA, 3 HOUS. J. HEALTH. L. & POL’Y 
1 (2002)).  
192 Id. at 1169 (“In any event, whether human semen, human tissues and organs are or 
are not biological products, they clearly are drugs when used for therapeutic purposes or to 
affect any bodily function and accordingly are subject to the requirements of the FD & C 
Act. The decision as to which Bureau within the FDA handles these products is entirely and 
administrative matter that raises no legal issue.”). 
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Although there is a statutory provision that permits the dual designation of 
products, which are also referred to as “combination products,” to the extent that 
certain innovations do not fall wholly within the categories of drug and biologic for 
example, Congress will likely need to revisit this statutory provision in the future.193 
“Dual designation” is less of a concern when it occurs with food and drugs or 
cosmetics and drugs such as Latisse, an FDA-approved treatment that grows lashes 
“longer, fuller and darker.”194 Dual designations in these categories of food and 
cosmetics do not tend to result in restrictions on medical practice; furthermore, dual 
designation products like Botox and Latisse are still on the market.195 While FDA 
officials have argued that knowing whether something is a drug, a biological 
product, “and/or” both is just an administrative determination, principles of good 
governance indicate that such an administrative determination should be clear.196 
The public should know how the FDA is classifying complex innovations and why 
it is classifying them in that manner. In other words, when it is unclear whether a 
product falls within the singular designation of “drug” or “biologic product,” a “dual 
designation” is similarly, if not more, unclear. Furthermore, legally, it is harder to 
know whether an agency decision is arbitrary and capricious with no clear 
understanding of why the agency decision (here, the initial classification) was 
made.197 Law is built on analogies and in the case of innovative techniques, those 
analogies are harder to construct; the burden of trying to construct those analogies 
and understand their applicability falls on the public when it should fall on the 
agency.  
 
C.  The Case for Regulatory Innovation, Even in the Absence of Jurisdiction: 
Marijuana Decriminalization 
 
As indicated by the above statement of the former Chief Counsel of the FDA, 
many—including current (and former) FDA employees—will take the position that 
the FDA does have jurisdiction over innovative techniques.198 This Section provides 
the normative basis for regulatory improvements even if the FDA does somehow 
have jurisdiction (or eventually obtains it through congressional mandate).199 While 
the discourse related to marijuana decriminalization currently focuses on issues such 
                                               
193 See 21 U.S.C. 353(g) (2018).  
194 HUTT ET AL., supra note 191, at 138–39, 118–121; see also Hear From the Experts, 
LATISSE, http://www.latisse.com/FAQs.aspx [https://perma.cc/T384-45GJ] (last visited Dec. 
3, 2018).  
195 See HUTT ET AL., supra note 191, at 117–120; see also BOTOX, 
https://www.botoxcosmetic.com/?cid=tab_lat_c [https://perma.cc/U4LF-YXJK] (last 
visited June 10, 2018).  
196 See HUTT ET AL., supra note 191, at 138–39, 118–121.  
197 See 5 U.S.C. § 706 (2016).  
198 See Bagley & Revesz, supra note 28.  
199 See infra Part IV (listing possible improvements for regulating the life sciences, 
including Congress creating a statute that clearly applies to the life sciences); supra Part II 
(discussing the FDA’s lack of jurisdiction over innovative life sciences techniques).  
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as increasing state tax revenues and criminal justice reforms, marijuana 
decriminalization, in large part, began with innovation related to the use of 
marijuana for medical purposes.  
After Gonzales v. Raich there is no doubt that the federal government has 
jurisdiction over the distribution of marijuana; however, much doubt exists as to 
whether the federal government should continue to regulate marijuana in the way 
that it does.200 Currently, marijuana is classified by the federal government as a 
Schedule I Controlled Substance.201 Schedule I Controlled Substances are drugs that 
have “a high potential for abuse,” that have “no currently accepted medical use in 
treatment in the United States,” and for the use of which “[t]here is a lack of accepted 
safety . . . under medical supervision.”202 Marijuana is currently categorized as a 
Schedule I Controlled Substance, despite growing evidence of its usefulness in 
medical treatment and the fact that no death from marijuana overdose has been 
reported.203 Heroin is also a Schedule I Controlled Substance, whereas cocaine, 
morphine, and opium are Schedule II Controlled Substances.204 Schedule II 
controlled substances “have a high potential for abuse which may lead to severe 
psychological or physical dependence.”205 Due to its classification, the possession 
or use of marijuana remains illegal under federal law in the United States, just as the 
possession or use of heroin remains criminalized.206 
Marijuana remains a Schedule I Controlled Substance even though States 
continue to decriminalize both medical and recreational marijuana uses. Even cities 
                                               
200 See Gonzales v. Raich, 545 U.S. 1, 9 (2005).  
201 See 21 U.S.C. § 812 (2018) (referring to the drug as “marihuana” on the list of 
Controlled Substances). 
202 Id.  
203 Id.; see also U.S. DRUG ENF’T ADMIN., DEA DRUG FACT SHEET: MARIJUANA 
(2018), https://www.dea.gov/druginfo/drug_data_sheets/Marijuana.pdf [https://perma.cc/ 
FFT6-TRHL]; Melina Delkic, Medical Marijuana’s Main Ingredient Isn’t Dangerous or 
Addictive, World Health Organization Report Says, NEWSWEEK (Dec. 14, 2017), 
http://www.newsweek.com/medical-marijuana-cbd-not-addictive-toxic-who-says-748069 
[https://perma.cc/MU7K-FCXK]. For more on the medical benefits of marijuana, see, for 
example, DUKE UNIVERSITY SCHOOL OF MEDICINE, CASARETT GIVES TED TALK ON 
MEDICAL MARIJUANA (2017), https://medicine.duke.edu/medicinenews/casarett-gives-ted-
talk-medical-marijuana [https://perma.cc/YU6X-39EN] (providing background information 
on Dr. Casarett’s research and a link to his TED Talk entitled A Doctor’s Case for Medical 
Marijuana).  
204 See U.S. DRUG ENF’T ADMIN., CONTROLLED SUBSTANCES BY CSA SCHEDULE 5, 8–
9 (2018), https://www.deadiversion.usdoj.gov/schedules/orangebook/e_cs_sched.pdf 
[https://perma.cc/4B5X-NMKQ]; see also, U.S. DRUG ENF’T ADMIN. DIVERSION CONTROL 
DIV., CONTROLLED SUBSTANCE SCHEDULES (2018), https://www.deadiversion.usdoj.gov/ 
schedules/#define [https://perma.cc/W2E5-WQWK] (“Examples of Schedule II narcotics 
include: hydromorphone (Dilaudid®), methadone (Dolophine®), meperidine (Demerol®), 
oxycodone (OxyContin®, Percocet®), and fentanyl (Sublimaze®, Duragesic®). Other 
Schedule II narcotics include: morphine, opium, codeine, and hydrocodone.”).  
205 See also U.S. DRUG ENF’T ADMIN. DIVERSION CONTROL DIV., supra note 204. 
206 21 U.S.C. §§ 843, 844 (2018).  
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have been actors in the decriminalization of marijuana.207 In 2005, a majority of the 
Supreme Court opined in Gonzales v. Raich, that California was known as a 
“pioneer” in marijuana regulation.208 Since then, California, which used to be at the 
forefront of discussions related to the decriminalization of marijuana due to its 
regime for medical marijuana use, has been replaced by Colorado.209 Colorado has 
expanded to decriminalizing the sale and use of marijuana, to the benefit of both 
commercial businesses and the state’s coffers.210 These actions continue despite the 
federal prohibitions on the possession and use of marijuana.  
Nonetheless, while statements of appointees—such as the Attorney General—
in the current Presidential administration indicate a hostility to state-based 
experimentation with medical and recreational marijuana, recently the 2017–18 
Secretary of Veterans Affairs “cautiously signaled a willingness to advance medical 
marijuana for veterans,” thus indicating that state-based experimentation with 
marijuana decriminalization may be impacting federal decision-making.211  
                                               
207 See, e.g., Grace Donnelly, Atlanta Is the Latest U.S. City to Decriminalize 
Marijuana. Here’s What that Means, FORTUNE (Oct. 3, 2017), 
http://fortune.com/2017/10/03/list-of-cities-that-decriminalized-marijuana/ [https://perma. 
cc/LSE9-W8WD]; see also Melanie Eversley, D.C. Marijuana Decriminalization Law Takes 
Effect, USA TODAY (Jul. 17, 2014), https://www.usatoday.com/story/news/nation/2014/07/ 
17/dc-marijuana-law/12770301/ [https://perma.cc/5WUD-EVVJ].  
208 Gonzales v. Raich, 545 U.S. 1, 5 (2005). 
209 See Steven B. Duke, The Future of Marijuana in the United States, 91 OR. L. REV. 
1301, 1302 (2013); see, e.g., David Matthews, Can Legal Marijuana Fund CPS? Lawmakers 
Learn How It’s Done in Colorado, DNA INFO (Apr. 19, 2017), 
https://www.dnainfo.com/chicago/20170419/downtown/can-legal-weed-help-fund-cps-
lawmakers-learn-how-its-done-colorado [https://perma.cc/G9JJ-V5CF]. (“Colorado is 
funding public schools and rehab programs with tax revenue from legalized marijuana—and 
it's time for Illinois [sic] do the same thing, state lawmakers were told Wednesday.”).  
210 Id. But see Sara Randazzo, Court Allows Colorado Couple to Sue Marijuana 
Growers, WALL ST. J. (June 7, 2017), https://www.wsj.com/articles/court-allows-colorado-
couple-to-sue-marijuana-growers-1496878545 [https://perma.cc/5GKU-ZNQQ] (discussing 
a federal appeals court in Denver giving “private landowners in Colorado the go-ahead to 
sue neighboring marijuana growers under a federal law targeting criminal enterprises, a 
decision that could expose the recreational marijuana industry to more private litigation”). 
211 See Joe Davidson, Will VA Chief Be Voice of Reason on Climate Change and 




.cc/HUJ9-8884] (discussing the position of then-Secretary of Veterans Affairs, David 
Shulkin, on the legalization of medical marijuana and its acceptance as a treatment method 
for those obtaining health care through the U.S. Department of Veterans Affairs); see also 
U.S. DEP’T OF VETERANS AFF., ABOUT VA (2018), 
https://www.va.gov/about_va/vahistory.asp [https://perma.cc/2UMX-GHYV]; see, e.g., 
Matt Zapotsky, et al., Use of Legalized Marijuana Threatened as Sessions Rescinds Obama-
Era Directive that Eased Federal Enforcement, WASH. POST (Jan. 4, 2018), 
https://www.washingtonpost.com/world/national-security/sessions-is-rescinding-obama-
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Here, the example of medical marijuana is also significant because it indicates 
that even if the FDA does happen to have jurisdiction over certain innovative 
technologies, the current development of marijuana decriminalization indicates that 
states may and should continue to create their own regimes to regulate innovative 
medical techniques, even when federal jurisdiction has been exerted. The next Part 
offers some suggestions as to how the regulatory apparatus applicable to the life 
sciences could be improved, with an emphasis on how individual states specifically 
could be better integrated into the regulatory scheme.  
 
IV.  SUGGESTIONS FOR IMPROVING THE REGULATION OF THE LIFE SCIENCES 
 
This Article has identified the shortcomings of the regulatory apparatus that the 
FDA uses to regulate innovations in the life sciences. There are, of course, many 
ways, in which this regulatory apparatus could be improved. For example, a regime 
that increases the role of states in regulating innovation in the life sciences would be 
an improvement due not only to the acknowledgement of state jurisdiction but also 
due to the increase in the variety of ethical perspectives that would be introduced 
into regulation (as opposed to the current singular view provided by the FDA).212 In 
the case of innovations in the biosciences, for example, Texas, Massachusetts, and 
California—states that are the sites of medical and scientific innovation—may create 
specific legal regimes in response to certain innovations such as those in stem cell 
treatments. And as other states see how these regimes are helpful to research, 
development, and patient care, other states may adopt such permissive regimes.213 
For example, as recent controversies—such as those surrounding the switch from 
prescription to over-the-counter Plan B and recent regulations increasing the number 
of entities that can opt out of the requirement that the “minimum essential benefits” 
offered by insurance companies include contraceptive benefits—emphasize, the 
U.S. Department of Health and Human Services, of which the FDA is a part, is not 
an independent regulatory agency.214 As such, ethical decisions may manifest in the 




212 See Lewis, supra note 13, at 1272–81.  
213 Massachusetts and California are known as sites for innovation. See, e.g., Bruce 
Booth, Why Biotech’s Talent, Capital and Returns are Consolidating into Two Key Clusters, 
FORBES (Mar. 21, 2017), https://www.forbes.com/sites/brucebooth/2017/03/21/inescapable-
gravity-of-biotechs-key-clusters-the-great-consolidation-of-talent-capital-returns/#3f025f5 
552e9 [https://perma.cc/RS2X-UGCW] (showing that Boston and San Francisco were the 
United States’ top “biotech clusters”). Colorado is discussed supra in the context of the 
autologous stem cell innovation that was the subject of U.S. v. Regenerative Sciences and in 
the context of marijuana decriminalization. See supra notes 209–210 and accompanying text; 
see also LATISSE, supra note 194. 
214 See, e.g., Robert Pear et. al., Trump Administration Rolls Back Birth Control 
Mandate, N.Y. TIMES (Oct. 6, 2017), https://www.nytimes.com/2017/10/06/us/politics/ 
trump-contraception-birth-control.html [https://perma.cc/RS2X-UGCW]; Julia Rover, 
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regulatory process, and they may not reflect the view of the citizenry in a particular 
state or the country as a whole. Furthermore, a regime in which States operate as 
laboratories could foster innovation in patient care, whereas the current federally 
focused regime does the opposite by effectively banning certain innovative medical 
techniques, both to the detriment of patient health and without adequate legal 
support.  
A natural objection to a regime with a state-based approach or that incorporates 
States into the federal regulatory process is that States do not have the competence 
to address issues related to innovative medical techniques and other issues that the 
FDA routinely addresses such as pharmaceutical and medical device safety. Yet, 
States have debated and enacted legislation related to scientific and medical 
research, informed consent, cloning, and ART, in addition to exercising state police 
powers in areas such as the licensing of physicians and medical personnel, the 
monitoring of epidemiological conditions, and the provision of health care services 
in the community.215 States are also the source for medical malpractice recovery as 
                                               
“Plan B” Gets FDA’s Over-Counter Approval, ALL THINGS CONSIDERED, NPR, (Aug. 24, 
2006), https://www.npr.org/templates/story/story.php?storyId=5705260 [https://perma.cc/ 
YK2H-DJ9B].  
215 See, e.g., CAL. HEALTH & SAFETY CODE § 111525 (2018) (“Consent; method and 
manner of obtaining”); 410 ILL. COMP. STAT. 50/3.1 (2018) (“Subjects of research programs 
or experimental procedures”); MD. CODE, HEALTH-GEN. § 13-2002 (2018) (“Construction 
with federal regulations”); NEV. REV. STAT. § 159.0805 (2018) (“Approval of court required 
before guardian may consent to certain treatment of or experiment on ward; conditions for 
approval”); N.Y. PUB. HEALTH LAW § 2442 (2018) (“Informed Consent”); 23 R.I. GEN. 
LAWS § 23-17-19.1 (2018) (“Rights of patients”) (2018); VA. CODE § 32.1-162.18 (2018) 
(“Informed Consent”); WYO. STAT. § 26-20-301 (2018) (“Clinical trials and studies coverage 
required”); Grimes v. Kennedy Krieger Inst. Inc., 782 A.2d 807 (Md. 2001) (discussing 
informed consent in nontherapeutic research); BARRY R. FURROW ET AL., HEALTH LAW: 
CASES, MATERIALS, AND PROBLEMS 87–88 (7th ed. 2013) (providing an overview of state 
licensing requirements for health care professionals); Adrienne N. Cash, Attack of the 
Clones: Legislative Approaches to Human Cloning in the United States, 4 DUKE L. TECH. 
REV. 1, 2 (2005) (providing an overview of state statutes that regulate cloning) (“To date, 
fourteen states have passed legislation pertaining to human cloning. The cloning laws of the 
fourteen states are similar to one another in that all ban reproductive cloning and impose 
rather stiff penalties for violators. Arkansas, Indiana, Iowa, Michigan, North Dakota, and 
South Dakota have extended the ban on cloning to cover therapeutic cloning as well as 
reproductive cloning. California, Connecticut, Massachusetts, New Jersey, Rhode Island, 
and Virginia have limited their bans to reproductive cloning. Missouri and Arizona have 
measures, which address the use of public funds for cloning without specifically prohibiting 
any form of cloning. Louisiana also enacted legislation prohibiting reproductive cloning; 
however the law expired in July 2003.” (citations omitted)); see also June Carbone, Negating 
the Genetic Tie: Does the Law Encourage Unnecessary Risks?, 79 UMKC L. REV. 333, 360 
(2010) (“Thus, federal oversight of the sciences has often involved federal research funding 
that sets the standards for industry practices as a condition of eligibility for government 
grants; with the federal ban on research using embryos, for example, California has 
authorized funding of stem cell research that has involved the state in creating research 
protocols that would ordinarily take place at the federal level.”). 
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there is no federal medical malpractice regime.216 States have also instituted product 
liability regimes that, before a 2011 Supreme Court decision, allowed them to 
provide greater protections for patients who were harmed by pharmaceuticals than 
did federal statutes and regulations.217 In the realm of life sciences innovation, 
California, for example, created the California Institute for Regenerative Medicine, 
after a majority of California voters approved “Proposition 71: the California Stem 
Cell Research and Cures Initiative.”218 The approval of Proposition 71 included the 
allocation of $3 billion towards the funding of stem cell research, which is 
distributed through the California Institute for Regenerative Medicine.219 States have 
also innovated in the legalization of marijuana in spite of now undisputed federal 
jurisdiction over controlled substances.220 
The decriminalization of medical and recreational marijuana indicates that, 
even if the FDA has jurisdiction over aspects of the life sciences that are related to 
the practice of medicine, this does not mean that the FDA should regulate innovative 
life sciences in the way that it currently does; states should continue to experiment 
in the regulation of these areas, despite federal assertion of jurisdiction, which, in 
the area of the life sciences, is far less clear than federal jurisdiction over controlled 
substances.  
It is also possible that, after not regulating “drugs” and innovative procedures 
for decades, states may find it difficult to develop new regulatory regimes due to 
lack of experience. One could argue that states are skilled at funding innovation but 
not necessarily at regulating innovation. Any newly developed regimes may, of 
course, vary in structure, and differing legal regimes may lead to forum shopping or 
an intra-American medical tourism. Yet, uniform statutes might resolve this issue 
as they have in other areas of innovation such as the Uniform Determination of 
Death Act.221 And even if not all fifty states adopt permissive regimes (or no States 
for that matter), this is still preferable to what amounts to a blanket prohibition on 
certain innovations by the federal government.222 Also, states share jurisdiction with 
                                               
216 See, e.g., Baber v. Hosp. Corp. of Am., 977 F.2d 872, 880 (4th Cir. 1992) (“[T]he 
(federal) Emergency Medical Treatment and Active Labor Act is no substitute for state law 
medical malpractice actions.” citing (42 U.S.C. § 1395dd(f) (2016) (EMTALA does not 
preempt state law, except to the extent state law directly conflicts with this statute)). 
217 See PLIVA, Inc. v. Mensing, 564 U.S. 604, 608–09 (2011). 
218 See History, CAL. INST. FOR REGENERATIVE MED. (2015), 
https://www.cirm.ca.gov/about-cirm/history (last visited June 12, 2018) 
[https://perma.cc/4E6T-A2AZ].  
219 See Where CIRM Funding Goes, CAL. INST. FOR REGENERATIVE MED. (2015), 
https://www.cirm.ca.gov/about/where-cirm-funding-goes (last visited June 12, 2018) 
[https://perma.cc/H2AL-K4D9]. 
220 See discussion supra Part III.C.  
221 See generally Legislative Fact Sheet—Determination of Death Act, UNIF. L. 
COMM’N (June 20, 2018), http://www.uniformlaws.org/LegislativeFactSheet.aspx?title= 
Determination%20of%20Death%20Act [https://perma.cc/JSA2-X792] (noting that 37 
states, D.C. and the U.S. Virgin Islands have enacted the Uniform Determination of Death 
Act). 
222 See, e.g., Wash. Legal Found. v. Kessler, 880 F. Supp. 26, 36 (D.D.C. 1995) (“It 
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the federal government in other “complex” areas. For example, states have 
jurisdiction over some civilian uses of nuclear power, namely medical isotopes 
through the U.S. Nuclear Regulatory Commission’s Agreement States Program.223 
In this process, those states that wish to (and are able to) regulate the use of nuclear 
material with lowered proliferation concerns are permitted to do so.224 Any program 
with an increased role for state-involvement would be preferable because there is at 
least a chance for innovation, whereas, under the current regime, as indicated in Parts 
II and III, innovation is being broadly halted.  
Yet, there could still be a role for the federal government in the regulation of 
innovative life sciences. For example, Congress could update the Federal Food, 
Drug, and Cosmetic Act in a way that adds another definition that clearly applies to 
the life sciences. Nonetheless, the fact that the terms “biotechnology” and “life 
sciences” are so broad in scope would render such an effort difficult. Another option 
would be a system of shared jurisdiction in which jurisdiction is shared between the 
States and the federal government. Thus, options for an improved regulatory regime 
include (1) a state-based waiver process225; (2) a hybrid system of shared 
                                               
may be true, as FDA argues, that a company which disagrees with the ‘advice’ contained in 
FDA’s regulatory correspondence may disregard this advice, go ahead with its planned 
activities, and then challenge the constitutionality of any adverse FDA action in an 
enforcement proceeding. However, the reality of the situation, as alleged by plaintiff, is that 
few if any companies are willing to directly challenge the FDA in this manner. In the first 
instance, the company must expose itself to the FDA’s power to seize an entire product line 
if the FDA finds the products to be ‘misbranded.’ Although the company can then litigate 
the validity of the seizure (and therefore the policy pursuant to which the seizure was made), 
the prospect of lost sales and protracted litigation is understandably discouraging to these 
companies. In addition, the FDA wields enormous power over drug and medical device 
manufacturers through its power to grant or deny new product applications. It is evident that 
manufacturers are most reluctant to arouse the ire of such a powerful agency. The result, 
according to plaintiff, is that ‘FDA has been able to effectuate its policies without having to 
resort regularly to formal rulemaking.’”).  
223 See Agreement State Program, U.S. NUCLEAR REG. COMM’N (Aug. 31, 2017), 
https://www.nrc.gov/about-nrc/state-tribal/agreement-states.html [https://perma.cc/JSA2-
X792] (“NRC provides assistance to States expressing interest in establishing programs to 
assume NRC regulatory authority under the Atomic Energy Act of 1954, as amended. 
Section 274 of the Act provides a statutory basis under which NRC relinquishes to the States 
portions of its regulatory authority to license and regulate byproduct materials 
(radioisotopes); source materials (uranium and thorium); and certain quantities of special 
nuclear materials. The mechanism for the transfer of NRC’s authority to a State is an 
agreement signed by the Governor of the State and the Chairman of the Commission, in 
accordance with section 274b of the Act.”).  
224 Id.  
225 A state-based waiver process could be structured similar to the process that states 
follow for Medicaid. See generally About Section 1115 Demonstrations, MEDICAID.GOV 
https://www.medicaid.gov/medicaid/section-1115-demo/about-1115/index.html 
[https://perma.cc/BFR4-3ZW9] (last visited June 12, 2018). 
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jurisdiction226; (3) state-by-state regulation of the life sciences227; (4) a congressional 
change in the FDA’s method of regulating innovative medical techniques228; and/or 
(5) a newly designed regulatory pathway for innovative medical treatments that 
acknowledges the differences between innovative medical treatments and products 
that are traditionally regulated by the FDA.229 
 
                                               
226 A hybrid system of shared jurisdiction could operate similar to the system that the 
U.S. Nuclear Regulatory Commission has regarding civilian uses of nuclear material that 
have lower proliferation concerns such as the use of isotopes in medical treatment. See 
generally Agreement State Program, U.S. NUCLEAR REG. COMM’N (Aug. 31, 2017), 
https://www.nrc.gov/about-nrc/state-tribal/agreement-states.html [https://perma.cc/HS7L-
W3FJ] (“NRC provides assistance to States expressing interest in establishing programs to 
assume NRC regulatory authority under the Atomic Energy Act of 1954, as amended. 
Section 274 of the Act provides a statutory basis under which NRC relinquishes to the States 
portions of its regulatory authority to license and regulate byproduct materials 
(radioisotopes); source materials (uranium and thorium); and certain quantities of special 
nuclear materials. The mechanism for the transfer of NRC’s authority to a State is an 
agreement signed by the Governor of the State and the Chairman of the Commission, in 
accordance with section 274b of the Act.”). 
227 State-by-state regulation of the life sciences could operate similar to how states 
address the results of assisted reproductive technology or have enacted laws banning human 
reproductive cloning. See generally CHARLES P. KINDREGAN, JR. & MAUREEN MCBRIEN, 
ASSISTED REPRODUCTIVE TECHNOLOGY: A LAWYER’S GUIDE TO EMERGING LAW AND 
SCIENCE (2d ed. 2011) (discussing the state-by-state regulation of assisted reproductive 
technology). 
228 A Congressional change to FDA regulation could involve Congress introducing 
another definition that would fill the gap between drugs and biologics—two categories that 
innovative techniques in the life sciences tend to fall “in between.”  
229 See generally Designating an Orphan Product: Drugs and Biological Products, 
FDA (Feb. 16, 2018), https://www.fda.gov/ForIndustry/DevelopingProductsforRareDisease 
sConditions/HowtoapplyforOrphanProductDesignation/default.htm [https://perma.cc/77H3 
-28YK] (“The Orphan Drug Act (ODA) provides for granting special status to a drug or 
biological product (‘drug’) to treat a rare disease or condition upon request of a sponsor. This 
status is referred to as orphan designation (or sometimes ‘orphan status’). For a drug to 
qualify for orphan designation both the drug and the disease or condition must meet certain 
criteria specified in the ODA and FDA’s implementing regulations at 21 CFR Part 316. 
Orphan designation qualifies the sponsor of the drug for various development incentives of 
the ODA, including tax credits for qualified clinical testing. A marketing application for a 
prescription drug product that has received orphan designation is not subject to a prescription 
drug user fee unless the application includes an indication for other than the rare disease or 
condition for which the drug was designated.”). As the possible options mentioned in the text 
draw not only on both the administrative and health law literatures, but also address a number 
of areas such as innovation in insurance regulation, the FDA’s regulatory process (assuming 
the FDA has jurisdiction or continues to regulate in the absence of jurisdiction), resource 
constraints, the Prescription Drug User Fee Acts, and larger federalism concerns, the full 
consideration of these possible solutions will be the subject of a future article, which will 
focus on issues related to regulatory best practices and also federalism in the healthcare 
context. 




It is becoming increasingly difficult to differentiate between medical practice 
on the one hand, and drugs, biologics, and medical devices on the other. Procedures 
using human tissues as medical treatments do not fall within the categories of 
products that the FDA is empowered to regulate, and the FDA’s regulatory scheme 
is not structured to objectively regulate these innovative uses of human cells and 
tissues while simultaneously permitting innovation, nor is that regulatory scheme 
structured to accommodate the resource constraints faced by researchers and 
physicians in these areas.230 Although these techniques could treat ailments better 
than pharmaceuticals and current treatment protocols, patients are largely deprived 
of these beneficial innovations due to the federal administrative state’s 
encroachment into the practice of medicine. 
Much of this Article has focused on the relationships between the FDA, medical 
providers, and new technologies. The FDA, in spite of criticisms such as those 
mentioned regarding regulatory capture, generally enjoys a positive reputation in the 
area of drug regulation.231 This is, of course, not a perfect reputation, as the agency 
has played a role in a number of imperfect regulatory situations such as delayed 
action related to Vioxx and a political dispute (with regulatory implications) over 
the change from prescription to over-the-counter treatment of Plan B.232 
Nonetheless, when thinking of “drug” regulation, individuals tend to think of 
“drugs” as pharmaceuticals.  
The discovery of subterranean regulation in fields outside of ART suggests that 
FDA officials not only use a particularly risk-averse approach to regulating ethically 
fraught areas that may also be politically sensitive (e.g., forms of ART that might 
involve the destruction of embryos which implicate debates about inheritable genetic 
modifications, eugenics, and embryo destruction), but also to regulating other 
techniques that may be innovative such that they do not fit within the standard areas 
that the FDA tends to regulate. The current effect of the FDA regulating these 
techniques is that innovative techniques are subject to extensive regulation in the 
United States, often resulting in the chilling of progress or medical tourism, which 
essentially limits these techniques to individuals who can afford to obtain these 
treatments abroad.233 As commentary focuses on the expedited drug approval 
                                               
230 See, e.g., Millman, supra note 129 (discussing the costs of drug research and 
development).  
231 David Zaring, Regulating by Repute, 110 MICH. L. REV. 1003, 1004–05 (2012) 
(reviewing DANIEL P. CARPENTER, REPUTATION AND POWER: ORGANIZATIONAL IMAGE AND 
PHARMACEUTICAL REGULATION AT THE FDA (2010)).  
232 See, e.g., id. at 1014, 1009–11 (noting “Carpenter’s view of the decline of the 
agency’s reputation during the Bush Administration” and mentioning the discussion of legal 
issues related to Vioxx).  
233 See Peter S. Reichertz & Melinda S. Friend, Hiding Behind Agency Discretion: The 
Food and Drug Administration’s Personal Use Drug Importation Policy, 9 CORNELL J.L. & 
PUB. POL’Y 493, 495 (2000) (observing that “during the Laetrile Wars . . . [the] FDA 
successfully prohibited terminally-ill cancer patients from taking what they believed to be 
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process and the increased outlay of funds for research, it has largely ignored whether 
congressional response to the FDA’s innovation-hindering “power grabs” has been 
adequate. In other words, there has been an emphasis on innovation and the 
processes used by the FDA to approve products without asking whether innovative 
treatments should be subject to the FDA’s regulatory process at all.  
While the National Academies has recommended that federal agencies “engage 
with federal and state consumer- and occupational-safety regulators . . . [in order to 
address issues] that may confront new biotechnology products in the next 5–10 
years,” recent events indicate that this recommendation of such a storied body is not 
enough.234 “Engagements” are not legally sufficient. The current regime either (1) 
has an automatic chilling effect on research, or (2) results in lengthy enforcement 
proceedings and litigation for those who are inclined to challenge the FDA’s 
authority.  
Yet the question that should be asked before these engagements, is whether the 
FDA should be regulating uses of the human body as a treatment for medical 
ailments. Contrary to the position of various scholars, this Article has argued that it 
should not.235 While some scholars believe that agencies and their staff members are 
“[r]arely . . . interested in simply maximizing the agency budget or jurisdiction,”236 
the case studies in this Article indicate that, at least in the specific field of human 
tissue as a treatment to human ailments, the FDA has been rapidly expanding its 
jurisdiction.237 In light of jurisdictional gaps, the agency could be motivated by the 
idea that if the agency fails to regulate now, then it may never get to. Yet, regulation 
without jurisdiction is not the answer—it leads only to a regulatory and clinical 
environment where medical treatment occurs without innovation that could improve 
patient health and ultimately save lives. 
                                               
an effective and perhaps lifesaving unapproved drug,” even though some patients ventured 
to Mexico in order to obtain the drug); see also Barron H. Lerner, McQueen’s Legacy of 
Laetrile, N.Y. TIMES (Nov. 15, 2005), http://www.nytimes.com/2005/11/15/health/mcque 
ens-legacy-of-laetrile.html [https://perma.cc/L6UQ-BK2E]. 
234 See THE NAT’L ACADS. OF SCIS., ENG’G, & MED., PREPARING FOR FUTURE 
PRODUCTS OF BIOTECHNOLOGY 13 (The National Academies Press. 2017), available at 
http://www.nap.edu/read/24605/chapter/2 [https://perma.cc/4YF9-NS53].  
235 See, e.g., HUTT ET AL., supra note 191, at 1169. 
236 Seidenfeld, Who Decides Who Decides, supra note 112, at 642. 
237 See id. at 643 n.136 (“That ‘single mission agencies’ may have ‘dedicated but 
zealous’ staff, which needs to be checked by political oversight outside the agency is a 
commonly cited excerpt from an administrative law opinion” (citing Sierra Club v. Costle, 
657 F.2d 298, 406 (D.C. Cir. 1981))). 
